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Abstract
Tissue engineering can be applied to develop therapeutic techniques for osteoarthritis, a
degenerative disease caused by the progressive deterioration of cartilage in joints. An
inherent goal in developing cartilage-replacement treatments is ensuring that tissue-
engineered constructs possess the same properties as native cartilage tissue. Biochemical
assays and imaging techniques can be used to study some of the main components of
cartilage and assess the value of potential therapies.
Agarose and self-assembling peptides have been used to make hydrogels for in vitro culture
of bovine bone marrow stromal cells (BMSCs) which can differentiate into chondrocytes,
undergo chondrogenesis, and produce cartilage tissue. So far, differences in cell
morphology that characterize chondrogenesis had been observed in peptide hydrogels like
KLD and RAD but not in the 2.0% agarose hydrogels typically used for culture. A tissue
engineering study was conducted to determine if a suitable environment for cell
proliferation and differentiation could be obtained using different agarose compositions.
BMSCs were cultured in 0.5%, 1.0%, and 2.0% agarose hydrogels for 21 days following
TGF-p1 supplementation. Results indicate that the 0.5% agarose hydrogels are clearly
inferior scaffolds when compared to the 1.0% and 2.0% agarose hydrogels, which are
generally comparable. Since agarose gels appear to be suboptimal in promoting
chondrogenesis, self-assembling peptides should be used in future studies.
In addition to the biochemical assays traditionally used in cartilage tissue engineering
studies, atomic force microscopy (AFM) can be used to image aggrecan, one of the main
components of cartilage. Imaging studies were carried out using fetal bovine epiphyseal
aggrecan to optimize previous extraction and sample preparation procedures, as well as an
AFM imaging protocol, for samples containing aggrecan. Experiments were conducted with
10, 25, and 50 ptg/mL aggrecan solutions to find the minimum concentration needed to
create aggrecan monolayers on APTES-mica that would yield acceptable AFM images (25
3
ptg/mL). AFM instrument and software parameters were optimized to find the working
range of the integral and proportional gains (0.2 - 0.4 and 0.6 - 0.8, respectively) and to
increase the resolution, showing fields at the 800 nm level. Finally, an image processing
protocol relevant to these molecules was established.
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Chapter 1: Introduction
1.1 Osteoarthritis and Current Treatments
Osteoarthritis (OA), sometimes called degenerative joint disease, is the most common form
of arthritis. It affects over 27 million people in the United States, particularly women over
the age of 40 and the elderly [1.1]. People who are overweight, have suffered from joint
injury, exhibit muscle weakness, or have bone deformities present an increased risk of
developing this disease [1.2].
The main cause of osteoarthritis is the progressive deterioration of the cartilage that
cushions bones in joints, specifically joints in the hands, hips, knees, and spine. As seen in
Figure 1.1, the smooth surface of the cartilage becomes rough and, eventually, the cartilage
may wear down completely, causing the bones at the affected joint to rub against each
other [1.3]. As one would expect, this results in pain, stiffness, or loss of flexibility in the
joints. Other characteristic symptoms of CA include swelling of the joints, a grating
sensation when using the affected joint, and the presence of bone spurs or hard lumps that
involve physical deformation [1.2, 1.3].
Osteoarthritis symptoms often develop slowly and worsen over time. Joint pain and
stiffness may become severe enough to make getting through the day difficult, if not
impossible. A French study found that more than 80% of clinical CA patients reported
limitations in their daily lives, including basic tasks, work, and leisure activities [1.4]. As a
result, people with CA can often feel desperate or frustrated when coping with their new
limitations, which may lead to depression or other mental disorders [1.5].
Treatments depend on the severity of the disease. For mild to moderate OA, treatments
include rest, exercise, physical therapy, losing weight, pain relievers, and drugs like
acetaminophen or ibuprofen. Patients with severe OA may need to resort to stronger
painkillers, cortisone shots, or even surgery such as joint replacement, realigning bones,
and cleaning up the area around the joint. Unfortunately, there is no cure for osteoarthritis
and the treatments available only alleviate symptoms temporarily [1.2, 1.6].
1.2 Cartilage and Aggrecan
Cartilage is an elastic and flexible connective tissue found in many areas of the body
including intervertebral discs, the ear, the nose, and joints between bones. As such, some
of the main functions of cartilage are providing structural support for body tissues,
improving movement by reducing friction between bones, and preventing joint damage by
acting as a shock absorber [1.7, 1.8].
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Some of the main types of this tissue are fibrous, elastic, and articular cartilage. Fibrous
cartilage may be found in areas like the intervertebral discs of the spinal cord, while elastic
cartilage is located in places such as the outer ear, nose, and larynx. Articular cartilage, or
hyaline cartilage, can be found in the joints between bones, notably in areas like the knees
and the hips [1.7]. As observed in patients with osteoarthritis, articular cartilage does not
regenerate in adults. Although superficial damage can heal in the very young, for all
practical purposes injuries to hyaline cartilage heal with fibrous cartilage which has
inferior weight-bearing properties [1.8, 1.9].
Hyaline cartilage functions as a low-friction, wear-resistant tissue designed to bear and
distribute loads. This tissue is composed of specialized cells called chondrocytes that
produce an extracellular matrix (ECM) rich in collagen fibers, proteoglycans, and other
proteins and biomolecules, giving articular cartilage its characteristic mechanical
properties [1.10]. Although cells make up only about 5% of the wet weight, chondrocyte
metabolism is responsible for the maintenance of a stable and abundant ECM. The balance
between anabolism and catabolism of the matrix is crucial for articular cartilage
homeostasis and providing hyaline cartilage with viscoelastic and mechanical properties
for efficient load distribution. [1.8]
Collagens are involved in defining structural integrity and some physiological functions of
neighboring cells within cartilage tissue. Additionally, collagen degradation and disturbed
metabolism are important in the course of OA [1.10]. There are many types of collagen,
each with different properties. Type II collagen is the characteristic and predominant
component of cartilage. It has the ability to assemble into highly oriented fibril aggregates
that help mediate the interaction with proteoglycans. Fibrous cartilage contains type III
collagen and is less durable than articular cartilage [1.7, 1.11].
Aggregating proteoglycans and other hyaluronan-binding proteins enmeshed in the
collagen matrix provide the complex mechanism that allows cartilage tissue to resist
deformation. These molecules contribute to the material and biological properties of the
matrix and regulate cell and tissue function [1.11, 1.12]. The proteoglycan superfamily
contains more than 30 full-time molecules that fulfill a variety of biological functions. For
instance, proteoglycans act as tissue organizers, influence cell growth and the maturation
of specialized tissues, play a role as biological filters, regulate collagen fibrillogenesis and
skin tensile strength, and influence corneal transparency. The presence of aggregating
proteoglycans in the ECM confers a high fixed negative charge density due to the numerous
chondroitin sulfate chains, and can have important effects on the material properties and
permeability of the matrix [1.12].
One of the prevalent molecules in the cartilage ECM is aggrecan, depicted in Figure 1.2
[1.13]. This aggregating proteoglycan has a high concentration of charged chondroitin
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sulfates and has covalently attached glycosaminoglycan (GAG) side chains, as well as a
small number of keratan sulfate chains. There may be about 100 chondroitin sulfates per
aggrecan molecule. Aggrecan has a tridomain structure: an N-terminal domain that binds
hyaluronan, a somewhat central domain that carries the glycosaminoglycan side chains,
and a C-terminal region that binds lectins [1.12].
GA is characterized by the damage or destruction of the aforementioned components of
cartilage. Molecules originating from articular cartilage, including aggrecan and type II
collagen fragments, are usually released as degradation products as a result of catabolic
processes. Therefore, these molecules serve as biomarkers that reflect quantitative and
dynamic changes in the degradation products of cartilage, providing a means of identifying
patients at risk for rapid joint damage and also for early monitoring of the efficacy of
disease-modifying therapies [1.8, 1.10].
Aggrecan can also be used as a biomarker to test the potential of tissue-engineered
constructs as cartilage substitutes. Thus, the ability to image aggrecan and assess its
structural properties on a molecular scale is an asset to the field of cartilage tissue
engineering. Atomic force microscopy (AFM) can be used to obtain such images and assist
in our understanding of OA and, ultimately, in developing tissue-engineered cartilage
replacement therapy [1.13].
1.3 Cartilage Tissue Engineering
Tissue engineering principles can be applied to develop therapeutic techniques to combat
the progression of OA and even to produce cartilage substitutes to replace damaged tissue
[1.14, 1.15]. Even though tissue engineering techniques have been used to produce
cartilage-like tissues, it is important to ensure that these constructs maintain the same
functional properties as native cartilage tissue.
A common cell source used in cartilage tissue engineering is bone marrow stromal cells
(BMSCs), which can easily be cultured and expanded in vitro. These cells include
mesenchymal progenitors capable of differentiating into cartilage tissue [1.16]. Cultured
cells must be able to produce cartilage through a process called chondrogenesis. In culture,
desired cellular differentiation and stimulation of chondrogenesis is achieved by using
transforming growth factor p (TGFjp) [1.17].
One approach to tissue engineering involves inducing previously isolated cells to produce a
tissue analog with composition, structure, and function approaching that of native cartilage
tissue. Cells are usually encapsulated in three-dimensional matrices such hydrogels that
serve as support structures and have been shown to help the cells maintain a chondrocytic
phenotype during long-term culture [1.18].
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Self-assembling peptide hydrogels, a new class of biomaterials, have shown to have many
applications in biotechnology. These materials allow for study and manipulation of cells
and may be used as novel scaffolds for tissue engineering and potential drug delivery
vehicles [1.19]. Self-assembling peptide hydrogels have been applied in cartilage repair
strategies and have been shown to stimulate the production of a mechanically functional
ECM and cell division in constructs using chondrocytes [1.20]. Figure 1.3 shows a cartilage
tissue engineering system where chondrocytes have been cultured in self-assembling
peptide hydrogel disks. These successful constructs suggest the potential of peptide
hydrogels in culturing BMSCs.
1.4 Atomic Force Microscopy Imaging
As previously mentioned, aggrecan is an important biomarker in cartilage tissue
engineering, especially when assessing the viability of constructs as functionally equivalent
substitutes for native cartilage tissue [1.22]. Atomic force microscopy (AFM) can be used
to obtain nm-scale resolution images of numerous biological macromolecules, including
notable ECM constituents, in fluid and ambient conditions [1.23, 1.24].
Direct visualization of aggrecan molecules through AFM imaging has been achieved while
noting detailed intramolecular structures and probing mechanical properties [1.13].
Figure 1.2B shows the AFM height image of an individual aggrecan molecule isolated from
fetal bovine epiphyseal cartilage where individual GAG chains can be observed and distinct
resolution of the N-termianl globular domains from the CS/KS-substituted brush region has
been achieved [1.13].
AFM imaging makes determination of the number, spacing, dimensions, and conformation
of GAG chains and full-length molecules possible [1.25]. Consequently, the use of AFM
imaging techniques to study aggrecan is advantageous both for improving our
understanding of GA and for furthering the field of cartilage tissue engineering.
1.5 Thesis Overview
The objective of this thesis is to further the areas of cartilage tissue engineering and the
molecular imaging of aggrecan through discovery and optimization studies.
This chapter has provided ample background on osteoarthritis and developing treatments
for this degenerative joint disease using tissue engineering. Cartilage, the key molecules in
this tissue, and the study of said molecules via AFM imaging have also been discussed.
Chapter 2 describes a cartilage tissue engineering experiment using bone marrow stromal
cells aimed at finding the optimal agarose hydrogel composition for culturing these cells.
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Chapter 3 expands on an atomic force microscopy assay for the study of native cartilage
and tissue engineered constructs, including different measures that were taken to find the
optimal sample preparation conditions and imaging settings.
Finally, Chapter 4 includes a summary of the main findings and suggestions for further
work motivated by this thesis.
Note that all figures and references will be included at the end of each chapter.
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1.6 Figures
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Figure 1.1 Progression of Osteoarthritis in the Knee. The early and late stages of osteoarthritis
are depicted in a knee joint where we can see how articular cartilage is degenerated over time,
affecting the adjoining bones in this joint. With generally asymmetric cartilage degradation, the joint
becomes malaligned, which in turn causes abnormal joint wear and even reactive bone formations or
osteophytes [1.21].
B.
KS CS
C
cp GAG
Figure 1.2 Aggrecan Molecule. (A) Diagram of a single aggrecan molecule indicating the G1, G2,
and G3 domains, keratan sulfate chains (KS), chondroitin sulfate chains (CS), the interglobular
domain (IGD), the core protein (cp), glycosaminoglycan chains (GAG), and the N- and C-terminus.
(B) AFM height image of an individual aggrecan molecule isolated from fetal bovine epiphyseal
cartilage [1.13].
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Figure 1.3 Cartilage Tissue Engineering System. Peptide hydrogels were used as scaffolds to
culture chondrocytes. The left panel shows a light microscope image of chondrocytes encapsulated
in peptide hydrogel. A chondrocyte-seeded, peptide hydrogel disk, along with its dimensions, can be
seen in the panel on the right [1.20].
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Chapter 2: Culture of Bone Marrow Stromal Cells in Agarose
Hydrogels
2.1 Introduction
Tissue engineering principles can be used to develop treatments for osteoarthritis and
even to produce replacements for damaged cartilage tissue. The ultimate goal of tissue
engineering approaches is to induce previously isolated cells to produce a tissue analog
with composition, structure, and function approaching that of native cartilage tissue, which
can later be implanted into a joint [2.1, 2.2].
Some of the main factors that must be established when designing a tissue-engineered
construct are the type of cells that will be cultured, the type of scaffolds that will serve as
their support structures, and the growth factors that will be used to obtain the desired
tissue. A common cell source used in cartilage tissue engineering is bone marrow stromal
cells (BMSCs), which can easily be cultured and expanded in vitro. These cells include
mesenchymal progenitors capable of differentiating into cartilage tissue [2.3, 2.4].
BMSCs can be induced to undergo the desired cellular differentiation using transforming
growth factor P (TGFp), which serves to stimulate cartilage production through
chondrogenesis [2.5]. Members of the TGF3 superfamily have been found to play roles in
chondrocyte growth, differentiation, proliferation, migration, and extracellular matrix
synthesis in different cell types, including chondrocytes and chondrogenic progenitor cells
[2.6, 2.7].
Hydrogels composed of biomaterials like alginate, agarose, and self-assembling peptides
are commonly used as scaffolds for tissue engineering [2.8, 2.9]. Investigators have found
that agarose gels used to culture chondrocytes isolated from bovine, rabbit, and human
sources help maintain cell phenotype and promote synthesis of a mechanically functional
ECM with nominal levels of type II collagen and cartilage-specific aggrecan [2.10].
Similarly, self-assembling peptide hydrogels such as KLD and RAD have been applied in
cartilage repair strategies and have been shown to stimulate ECM production and cell
division in constructs using chondrocytes. This suggests their potential as peptide
hydrogels for culturing BMSCs [2.11].
It is known that changes in cell morphology indicate proliferation and the start of
chondrogenesis. As seen in Figure 2.1, morphology images of bovine BMSCs encapsulated
in hydrogel scaffolds indicate that changes in cell morphology occurred in self-assembling
peptide hydrogels (i.e., KLD and RAD) during the first four days of TGFs supplementation
but not in 2% agarose hydrogels [2.12].
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Given that so far the differences in cell morphology that characterize chondrogenesis have
been observed only in peptide hydrogels, it is important to verify if this favorable trend can
be achieved using other materials. Agarose is a well studied gel that is more convenient to
work with when compared to peptide gels. Studies typically include 2.0% agarose gels but
this concentration may not provide the adequate mechanical properties for the optimal
culture environment [2.10, 2.12]. What's more, studies using agarose gels in the past have
indicated that 1% gels can cause chondrocytes to dedifferentiate while 2% gels are optimal
for culture [2.13].
The main objective for this experiment is to verify if the differences in cell morphology that
are typical of chondrogenesis and have been observed in peptide hydrogels can be
achieved using agarose hydrogels. We also seek to gain a better understanding of the
process of chondrogenesis, particularly in its initial stages. As a result, BMSCs will be
cultured in agarose hydrogels of different concentrations to identify which scaffold best
promotes chondrogenesis.
2.2 Materials and Methods
For this study, BMSCs were isolated from bovine calves and then encapsulated in 0.5%,
1.0%, and 2.0% agarose hydrogels assembled as disks such as those in Figure 1.3. The
BMSC-seeded hydrogels were cultured for 21 days following TGF3 supplementation and
several assays were performed to measure key properties and biochemical markers
relevant in cartilage tissue engineering.
Isolation and Expansion of BMSCs
BMSCs were isolated from the femoral and tibial diaphyses of a bovine calf. After removing
all connective tissue and muscle around each bone, sterilized hand-saw blades were used
to bisect the bones at the mid-diaphysis. The exposed bone marrow was extracted from
the medullary cavity with forceps and stored in PBS containing 1% PSA (100 U/mL
penicillin, 100 pg/mL streptomycin, and 250 ng/mL amphotericin). The bone marrow was
mechanically disrupted and the fat content was removed via centrifugation at 1000 g for 15
minutes. The pellet was resuspended in PBS and further homogenized by subsequently
passing the material through 16- and 18-gauge needles and a 70 Im cell strainer.
The nucleated cell count was then obtained by diluting a portion of the cell suspension in
Ammonium Chloride-Tris Base using the Trypan Blue. After centrifugation at 200 g for 15
minutes, the cell pellet was resuspended in a culture medium that consists BMSC
Expansion Medium (low glucose DMEM with 10% ES-FBS, 1% HEPES, and 1% PSA)
supplemented with lng/mL bFGF. Approximately 75 x 106 cells were pre-plated and
incubated for 30 minutes to allow rapidly-adhering cells to attach. The media and non-
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adherent cells were transferred to another T-flask and additional BMSC Expansion Medium
was added for approximately 1x 106 cells/cm 2 in 15 mL of media.
After two days in culture, the media was exchanged for fresh BMSC Expansion Medium
after and flasks were cultured until cells were nearly 75-80% confluent (Passage 0, PO).
The cells that adhered to the T-flask wall were removed with 0.05% trypsin-EDTA,
centrifuged at 200 g for 15 minutes, resuspended in PBS, and the nucleated cell count was
obtained again via the Trypan Blue exclusion method. Finally, the cells were cryopreserved
and frozen in aliquots of 5 million cells/vial using liquid nitrogen.
See Appendix A.1 for more details on this protocol.
Thaw and Expansion of Cryopreserved BMSCs
Cryopreserved cells were rapidly thawed at 37'C and resuspended in high glucose DMEM.
Following centrifugation at 200 g for 8 minutes, the cell pellet was resuspended in BMSC
Expansion Medium (low glucose DMEM with 10% ES-FBS, 1% HEPES, and 1% PSA) and the
cells were counted via the Trypan Blue exclusion method in order to calculate the
parameters for seeding the BMSCs into flasks for culture. Cells were cultured in T-flasks at
6000 cells/cm 2 in BMSC Expansion Medium with 5 ng/mL FGF at 37'C for three days.
BMSCs were detached from the culture-treated walls of the T-flasks by incubating the
flasks with trypsin at 37'C for 4 minutes after having removed the media and washed with
PBS. FBS Medium was added to each T-flask to inactivate the trypsin and all flasks were
combined after subsequent washing with the new media. The cells were counted via the
Trypan Blue exclusion method in order to calculate the parameters for the next passage.
BMSCs were cultured in T-flasks at 6000 cells/cm 2 in FBS Medium with 5 ng/mL FGF at
37'C for three days in preparation for encapsulation in hydrogels.
See Appendix A.2 for more details on this protocol.
Encapsulation of BMSCs in Agarose Hydrogels for Culture
Custom three-piece casting molds were used to make 2% agarose rings whose hollow
centers can be filled with hydrogels as seen in Figure 2.2. Once the acellular agarose rings
solidified, the molds were removed and the rings were equilibrated in Casting Medium
(high glucose DMEM with 25mM HEPES, 1% ITS+1, 1% NEAA, 1% Na Pyr, 1% PSA, and
0.4% Proline) at 37'C. The 0.5%, 1.0%, and 2.0% agarose solutions for cell encapsulation
were prepared by dissolving the stock agarose solution to the desired concentration in
sterile 10% sucrose.
Cells were treated with trypsin and inactivated with FBS Medium (low glucose DMEM with
10mM HEPES, 10% ES-FBS, and 1% PSA) for subsequent centrifugation and resuspension
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in FBS Medium. Aliquots with 15 x 106 cells in 2 mL sterile tubes were centrifuged at 100 g
for 5 minutes. Meanwhile, the agarose rings were prepared for casting by aspirating the
media, leaving the wells completely dry.
The casting portion of this procedure is a two-person job given that it requires optimal
timing and speedy work. The team must aspirate the media from the 2 mL tubes and
resuspend the cell pellets in 300 ptL of sterile 10% sucrose with 2.5mM HEPES. They must
then inject the cell suspension into the desired hydrogel solutions and use a repeater
pipette to dispense 50 ptL of the cell-seeded hydrogel suspension into the center of each
agarose ring. Finally, each well is covered with Casting Medium, which is then substituted
by Culture Medium supplemented with 1Ong/mL of TGFp. Cells were incubated at 37'C
with media changes every 2-3 days [2.14].
See Appendix A.3 for more details on this protocol. Appendix A.4 contains details for
subsequent cell culture media changes and sampling.
Cell Viability and Morphology Assay
The Live/Dead assay was used to obtain a qualitative picture of cell viability and evaluate
cell morphology. Sterilized tools were used to remove the exterior agarose rings from
desired BSMC-seeded hydrogels and place them in microscope slide wells with PBS 1X.
Samples were then dyed with 12.5 ptg/mL of fluorescein diacetate for viewing live cells and
350 ng/mL of ethidium bromide for viewing dead cells. A Nikon Eclipse Fluorescent
Microscope was used to image samples and identify live cells, which appear green in color,
and dead cells, which appear red in color.
See Appendix A.5 for more details on this protocol.
Lyophilization and Proteinase K Digestion
Samples were freeze-dried and their final lyophilized weights were obtained. Hydrogel
samples were then digested using 0.25 mg/mL Proteinase K so that specific biomolecules
can be detected through the GAG Assay, DNA Assay, and Radiolabel Incorporation Assay.
See Appendix A.6 for more details on this protocol.
GAG Assay
This assay was used to determine the sulfated glycosaminoglycan (GAG) content in the
tissue-engineered constructs. Samples were stained with dymethylmethylene blue
(DMMB) dye, which indicates the presence of chondroitin sulfate and keratan sulfate found
within GAG chains. A standard concentration curve was prepared using chondroitin-6-
sulfate solutions in Tris Buffer. Samples and standards (20 ptL) were distributed along a
clear 96-well plate, stained with 200 piL DMMB dye, and readings were obtained at a 520
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nm wavelength in the Maxy machine for data processing in terms of GAG concentration
(ptg/mL).
See Appendix A.7 for more details on this protocol.
DNA Assay
The DNA Assay uses bisbenzimidazole fluorescent dye Hoechst 33258 to stain DNA present
in experimental samples. The interaction of Hoechst 33258 with DNA requires at least four
consecutive A-T base pairs, as well as dissociation of DNA from proteins of the
nucleoprotein complex. The former is satisfied by random chance, while the latter was
accomplished by Proteinase K digestion.
A standard concentration curve was prepared using a 10 pg/mL DNA stock in Tris Buffer.
Samples and standards (20 [tL) were distributed along a black 96-well plate, stained with
200 iiL 0.1 ptg/mL Hoechst 33258 DNA Dye Solution, and readings were obtained in the
Victor machine for data processing in terms of DNA concentration ([tg/mL).
See Appendix A.8 for more details on this protocol.
Radiolabel Incorporation Assay
The objective of this assay is to examine cell proliferation and proteoglycan synthesis by
radiolabeling samples with 3H-Thymidine and 3 5S-Sulfate, respectively. In order to label
the samples, the ITS Medium was supplemented with calculated amounts of the desired
isotopes (i.e., 5 pCi/mL 35S and 10 ptCi/mL 3H) while preparing the 35S and 35s 3H standards
needed for scintillation counts later on. Each cell-seeded hydrogel sample was cultured
with 750 iiL of the radiolabeled media at 37'C for 24 hours to ensure isotope incorporation.
Once at the 24-hour point, the radiolabeled media was removed from each well and
samples were submitted to four consecutive washes to remove unincorporated isotopes.
For each wash, 1mL of Rx Wash was added to all radiolabeled hydrogels within the 24-well
plate, which was incubated for 30 minutes in a refrigerator to slow cell metabolism and
maintain viability. Washed samples were then transferred to pre-weighed vials after
removing the 2% agarose rings surrounding the plugs and the wet weight of each hydrogel
was obtained.
A scintillation counter was then used to measure the levels of radioactivity given off by
samples which have been tagged with 3 H and 35S. Finally, the levels of protein synthesis
(3 H) and proteoglycan synthesis ( 3 5S) were calculated from the readings for the
corresponding isotopes, converted to concentrations (nmol), and normalized by DNA
content and gel weight (nmol/pg/mL/mg).
See Appendix A.9 for more details on this protocol.
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2.3 Results and Discussion
Various assays were performed on the tissue-engineered constructs throughout the 21-day
culture to measure several properties of interest such as cell viability and morphology, GAG
content, DNA levels, gel contraction, cell proliferation, and proteoglycan synthesis.
Cell Viability and Morphology Assay
The Live/Dead Assay was used to assess the viability and get an idea on the morphology of
cultured cells. A visual comparison of the live and dead cells, illustrated in Figure 2.3,
indicates that viability was excellent and therefore not a cause for concern in proceeding
with experiments and analyzing results. More importantly, it is evident that the BMSCs
retained a spherical morphology in all agarose hydrogels both at Day 4 and Day 7 of
culture. The fact that the cells did not exhibit changes in morphology like those observed in
Figure 2.1 suggests that though agarose hydrogels with concentrations below 2.0% might
provide a microenvironment more mechanically similar to in vivo surroundings, they are
not suitable for promoting chondrogenesis. This conclusion points to the use of self-
assembling peptide hydrogels as a superior scaffold for cartilage tissue engineering.
GAG Assay
Figure 2.4 shows how this assay was used in determining the GAG content in the cultured
chondrocytes at Days 0, 4, 7, and 21. For the most part, GAG concentrations gradually
increased over time. However, the 0.5% agarose hydrogels are significantly lower. The
overall levels of GAG concentration are low compared to the usual 50-100 ptg/mL for
agarose observed in similar samples at our lab. They are not very high when compared to
Day 0 levels either. Importantly, the BMSCs cultured in 0.5% agarose hydrogels don't seem
to produce GAG. This suggests that scaffolds made with 0.5% or less agarose are not fit for
the development of chondrocytes or differentiated BMSCs. A lingering question is whether
GAG is being lost to the media and if this effect could be due in part to the observed gel
contraction. Though the media was saved during the course of this experiment, analyses
could not be performed due to logistical difficulties in sample storage. The saved media
samples are no longer available.
DNA Assay and Gel Contraction
Figure 2.5 shows the DNA concentration for the cell-seeded hydrogel samples at key time
points throughout the experiment. It is apparent that DNA levels decreased by Day 21,
which is expected as the culture period progresses. Levels are comparable to those
obtained in previous experiments at our lab where samples contained 2-4 ptg/mL DNA. As
seen in Figure 2.5B, normalizing by DNA content shows higher amounts in the 0.5% and
1.0%, which is likely due to gel contraction.
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Figure 2.6 depicts the weights of the gels and how they change over time. Gel weights and
experimental observations show that 0.5% agarose gels contracted significantly more than
1.0% and 2.0% gels.
Radiolabel Incorporation Assay
In this assay, 3H-Thymidine was used as an indicator for cell proliferation while 3 5S-Sulfate
was used to evaluate proteoglycan synthesis. As seen in Figure 2.7A and Figure 2.7C, cell
proliferation seems to remain stable with the exception of 1.0% agarose gels at Day 7. This
is still within the margin of error indicated by the error bars in the figure. It is clear that
cells exhibit lower proliferation in 0.5% agarose gels.
Figure 2.7B and Figure 2.7D show proteoglycan synthesis through 35S incorporation. It is
apparent that proteoglycan synthesis is much lower for 0.5% agarose gels and slightly
lower for 1.0% gels. Overall synthesis remains fairly stable. However, the 1.0% agarose gel
at Day 7 seems to exhibit low or no proteoglycan synthesis. Since there is no reason to
expect these results, it may be possible that this is due to an unforeseen experimental
error.
2.4 Conclusions
The goal of this study was to determine if agarose hydrogel scaffolds could be used to
promote chondrogenesis in TGFI-supplemented BMSCs to the same extent as peptide
hydrogel scaffolds have done so in the past. The latter have been used in experiments
where the differences in cell morphology that are typical in chondrogenesis were observed
and cells were able to maintain nominal levels of biochemical markers relevant in cartilage
tissue engineering.
For our experiment, BMSCs were isolated from bovine calves, encapsulated in 0.5%, 1.0%,
and 2.0% agarose hydrogel disks, and cultured for 21 days after TGFp supplementation. It
was evident that cells in all agarose hydrogel scaffolds did not undergo changes in
morphology like those observed in peptide hydrogel scaffolds. What's more, all the agarose
gels contracted over time, particularly the low-concentration 0.5% gels.
As for assays examining biochemical markers, overall results indicate that the 0.5%
agarose hydrogels are clearly inferior when compared to the 1.0% and 2.0% agarose
hydrogels, which are generally comparable. It was clear that though GAG concentrations
gradually increased over time, cells in 0.5% agarose hydrogels had significantly lower GAG
levels and did not even seem to produce GAG. DNA levels decreased as time progressed
during the 21-day culture period. For the most part, cell proliferation and proteoglycan
synthesis remained stable while corresponding levels for 0.5% agarose hydrogels were
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notably lower. As a result, this experiment proves that scaffolds made with 0.5% or less
agarose are not fit for the development of chondrocytes or differentiated BMSCs.
In order to gain a better understanding of the initial stages of chondrogenesis, future assays
should include morphology imaging targeting actin networks and cell nuclei. This would
be helpful in seeing the changes that BMSCs undergo on a deeper level. Western Blots and
RT-PCR could also be used to verify the expression of genes characteristic of chondrocytes
(e.g., collagen II). Performing the GAG Assay for media samples to examine GAG lost to the
media would provide further insight into the BMSC culture process.
The overarching conclusion from this study is that agarose hydrogels, even those with
concentrations below the customary 2.0% and thus more mechanically similar to in vivo
cell surroundings, are not suitable for promoting chondrogenesis and cell proliferation.
This suggests that self-assembling peptide hydrogels are indeed a superior scaffold for
cartilage tissue engineering and should be used in future studies.
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Agarose RAD16-1 KLD12
Scale Bar = 50pm, Red = F-actin, Blue = DAPI
(nuclei)
Figure 2.1 Morphology Images for Bovine BMSCs Encapsulated in Self-Assembling Peptide
Hydrogel Scaffolds. Cells in different hydrogel scaffolds (i.e., agarose, RAD16-I, KLD12) were
stained such that F-actin can be seen in red and the nuclei can be observed in blue. (A) Cells retain
spherical morphology in all hydrogels at Day 0 after TGF@ supplementation. (B) Changes in cell
morphology, which indicate proliferation and the start of chondrogenesis, occurred in self-
assembling peptide hydrogels during the first four days of culture after TGFs supplementation but
not in 2% agarose [2.12].
Cell-seeded
Hydrogel (50pL)
Acellular
Agarose Mold
Figure 2.2 Cell Encapsulation in Hydrogels within Agarose Rings. Schematic of the agarose ring
molds surrounding cell-seeded hydrogel disks, including the dimensions of each component. [2.12]
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Figure 2.3 Cell Viability and Morphology for BMSC's Seeded in Agarose Hydrogels. Cells in
0.5%, 1.0%, and 2.0% agarose hydrogels were stained such that live cells appear green and dead cells
appear red. Cells are viable both at Day 4 (A) and Day 7 (B) of culture. Their morphology remains
spherical and changes such as those observed in self-asembling peptide hydrogels are not apparent.
Figure 2.4 GAG Assay. The total GAG concentration ([tg/mL) in the BMSC-seeded agarose hydrogels
of different concentrations can be seen over the 21-day culture period. Though GAG concentrations
generally increase over time, it is evident that the 0.5% agarose gels have significantly lower GAG.
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Figure 2.5 DNA Assay. (A) The total DNA concentration (ptg/mL) in the BMSC-seeded agarose
hydrogels of different concentrations can be seen over the 21-day culture period. (B) The DNA
concentrations have been normalized by gel weight.
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Figure 2.6 BMSC-Seeded Gel Weights. The average weight of the BMSC-seeded agarose gels can be
seen over the 21-day culture period. Though 1.0% and 2.0% agarose gels remained fairly constant in
weight, it is evident that 0.5% agarose gels contracted over time.
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Figure 2.7 Radiolabel Incorporation Assay. (A) Cell proliferation is indicated by the level of 3H
incorporation. (B) Proteoglycan synthesis is indicated by the level of 3 5S incorporation. (C) Cell
proliferation normalized by DNA content and gel weight. (D) Proteoglycan synthesis normalized by
DNA content and gel weight.
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Chapter 3: Atomic Force Microscopy Imaging Assay for Cartilage
Tissue Engineering
3.1 Introduction
Tissue engineering principles can be applied to develop treatments for OA and even to
produce replacements for damaged cartilage tissue. Even though tissue engineering
techniques have been used to produce cartilage-like tissues, the challenge of creating
constructs with biochemical, structural, and biomechanical properties that maintain the
same function as in vivo cartilage still remains [3.1, 3.2].
As one of the prevalent macromolecules in the cartilage ECM [3.3], aggrecan is an
important indicator when testing the potential of tissue-engineered constructs as cartilage
substitutes [3.4]. Its expression, synthesis, organization, and turnover are often used as
biomarkers of the chondrogenic potential of BMSCs [3.5, 3.6].
The overall composition of aggrecan can be assessed through biochemical [3.7],
chromatographic [3.8], and electrophoretic techniques [3.9], while biophysical methods
such as electron microscopy (EM) imaging can be used to observe details such as the thick
CS-brush region in aggrecan molecules. Still, images obtained through these methods do
not allow for a look at the fine details of molecular heterogeneity, conformation, and
structure at the level of individual aggrecan molecules [3.10, 3.11, 3.12].
The recent development of high-resolution atomic force microscopy (AFM) imaging
techniques allows for a direct visualization of detailed intramolecular structures and
probing of nanoscale mechanical properties of various ECM constituents, particularly
aggrecan [3.13, 3.14]. AFM imaging provides a better understanding of the molecule-to-
molecule variability of aggrecan, making determination of the number, spacing,
dimensions, and conformation of GAG chains and full-length molecules possible [3.15].
Thus, the ability to image aggrecan and assess its structural properties on a molecular scale
is an asset to the field of cartilage tissue engineering.
Atomic force microscopy (AFM) can be used to gain further insights into key components of
the ECM and assist in our understanding of OA and, ultimately, in developing tissue-
engineered cartilage replacement therapy [3.13, 3.15]. As seen in Figure 3.1A, aggrecan
molecules are immobilized on the APTES-mica substrate and imaged by a sharp silicon
probe tip. Figure 3.1B shows an example of resulting images, in this case of newborn
human aggrecan, where AFM allows for the distinct resolution of the G1 domain and the
individual GAG chains.
The main objective for this experiment is to learn about the theoretical and practical
aspects of atomic force microscopy while imaging aggrecan molecules. The sample
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preparation conditions needed to immobilize aggrecan on the mica surface for subsequent
imaging will be optimized. In addition, the range of instrument and software parameters
relevant to tapping mode AFM for imaging aggrecan molecules will be explored. This will
help in establishing a protocol for AFM imaging and image processing relevant to the
selected molecules.
3.2 Materials and Methods
For this study, fetal bovine epiphyseal aggrecan samples were used to optimize sample
preparation and imaging parameters with the goal of establishing a more thorough AFM
imaging protocol.
Sample Acquisition
Purified samples of aggrecan molecules isolated from the epiphyseal region of fetal bovine
femora, tibiae, and fibulae were acquired for this study. Fetal bovine cartilage was
obtained from the epiphyseal growth plate region, processed, and stored as described
previously [3.11, 3.16]. Purified aggrecan fractions (AlAlD1D1) were dialyzed
consecutively against 500 volumes of 1M NaCl and deionized water to remove excess salts
[3.13]. The GAG Assay was used to determine the concentration of aggrecan in purified
samples as described in the preceding chapter and detailed in Appendix A.7.
Sample Preparation
Aggrecan molecules must be immobilized on the mica surface for subsequent AFM imaging.
In order to achieve this, the surface was coated 0.01% v/v 3-aminopropyltriethoxysilane
(APTES) for an incubation time of 30 minutes at room temperature. APTES is an
immobilizing agent with a net positive charge to bind the aggrecan molecules [3.13].
The prepared APTES-mica surface was then incubated with the desired aggrecan solution
at concentrations ranging from 50-to-500 pg/mL for an incubation time of 20 to 60
minutes. The excess aggrecan solution was rinsed off with 200 p.L of purified water and the
APTES-mica surface was dried overnight, resulting in an aggrecan monolayer.
See Appendix A.11 for more details on this protocol [3.13, 3.15].
AFM Imaging
The APTES-mica surfaces with aggrecan monolayer samples were then taken for AFM
imaging using a NanoScope IlIa Multimode AFM. Sample surfaces were glued to the
magnet with custom adhesive tabs while using tweezers to handle the samples and avoid
contamination. Each containing a specific APTES-mica surface with an aggrecan monolayer
sample, the magnets were placed on top of the microscope's piezo tube for imaging. The
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key components of said microscope, as well as the manufacturer's schematic of the inner
workings of the microscope head and cantilever holder, can be observed in Figure 3.2.
A Super Sharp Silicon AFM tip with 4 [im thickness was used to probe the sample surface
through tapping mode AFM. Great care was taken to align the laser for optimum signal and
select the parameters for the software's feedback loop. These include the integral and
proportional gains, which are values ranging from 0 to 1 used to maintain constant
amplitude for tapping mode. Once the laser is manually aligned and initial parameters are
set up for imaging, the NanoScope Ila Multimode AFM is placed in a platform and
suspended in midair using a tripod and elastic cables in order to reduce ambient vibrations
and therefore minimize noise during image capture.
See Appendix A.11 for more details on this protocol [3.13, 3.15].
Image Processing
The established heuristic for image processing requires the NanoScope 5.31r1 and the
WSxM 4.0 Develop 10.1 software packages. The former was used to select the scan area,
resolution, and flatten the image for a more accurate depiction of the aggrecan molecule
height. The latter was used to adjust the color palette and equalize the image, allowing for
better contour definition of the image molecules. Figure 3.3 shows three consecutive
stages of image processing for a sample of fetal bovine epiphyseal aggrecan at a
concentration of 50 pg/mL can be seen in three consecutive stages of image processing.
See Appendix A.11 for more details on this protocol.
3.3 Results and Discussion
A number of tests were conducted using fetal bovine epiphyseal aggrecan samples to
optimize the sample preparation process for use with minimal sample volumes. The AFM
imaging technique was optimized in terms of the integral and proportional gains, as well as
the image resolution.
Sample Preparation: Test of Established Conditions
The recommended sample preparation conditions for aggrecan AFM imaging are 250
ptg/mL of aggrecan incubated for 40 minutes. Given the need to minimize the aggrecan
concentration needed to obtain quality images, the goal of this test was to test the range of
the established sample preparation conditions using fetal bovine epiphyseal aggrecan.
Samples were prepared with 200 and 250 ptg/mL aggrecan and incubated for both 20 and
40 min. As seen in Figure 3.4, aggrecan molecules can be successfully visualized at both
200 and 250 pg/mL concentrations. Incubating the sample solutions for longer periods of
time allows for more aggrecan molecules to attach to the APTES-mica surface, which is
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evident when comparing the 20 and 40 min images. Therefore, when using lower aggrecan
concentrations, longer incubation times will aid in promoting the attachment of molecules
to the APTES-mica surface.
Sample Preparation: Minimization of Aggrecan Concentration
Decent images of aggrecan molecules were obtained at high aggrecan concentrations (200 -
250 [tg/mL). Unfortunately, these conditions may still be too high for samples from tissue-
engineered constructs which usually yield lower amounts of aggrecan. The goal of this
imaging study was to find the minimum working conditions during aggrecan sample
preparation that would yield good AFM images.
As seen in Figure 3.5, fetal bovine epiphyseal aggrecan samples were imaged at 10, 25, and
50 ig/mL concentrations where all samples were incubated for 60 min. Ideally, one would
want to see distinct G1 domains and individual GAG chains along the length of the aggrecan
molecule, which would allow for the qualitative and quantitative assessment of certain
properties. It is evident that samples should be prepared at no less than 25 ptg/mL of
aggrecan to ensure representative images of the molecules. If the concentration is too low,
the aggrecan molecules tend to curl. This phenomenon has been observed in previous
studies and may merit further analysis [3.13].
AFM Imaging: Integral and Proportional Gains
The integral and proportional gains are fundamental components of the feedback control
loop used to maintain constant amplitude for imaging via tapping mode AFM. The higher
the gains are set, the better the tip will track the sample topography. However, higher
gains tend to cause noise. The goal of this imaging experiment imaging was to find an
optimal combination of parameters by imaging the same sample section while varying the
integral and proportional gains.
Figure 3.6 shows the different parameter combinations alternated while imaging a fetal
bovine epiphyseal aggrecan sample (25 pg/mL, 60 min). Results indicate that the optimal
range for the integral gain should be 0.2-0.4, while the proportional gain works best at 0.6-
0.8. Figure 3.7 shows further detailing of this data. It is important to note that the
proportional gain is dependent upon the integral gain so these parameters should be
adjusted simultaneously. For instance, if the integral gain is decreased, the proportional
gain should be decreased as well.
AFM Imaging: Image Resolution
Previous images show aggrecan molecules within fields at the 2 Im level. Some of these
images, unfortunately, do not show enough detail on the molecules. Thus, the goal of this
test is to obtain higher-resolution images, preferably at the single-molecule level.
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Figure 3.8 shows a fetal bovine epiphyseal aggrecan sample (25 pg/mL, 60 min) at 2 [rm, 1
prm, 800 nm, and 500 nm levels. Results indicate that the resolution can be increased to
show imaging fields at the 800 nm level with minimal noise.
3.4 Conclusions
The goal of this study was to learn about the theoretical and practical aspects of atomic
force microscopy while imaging aggrecan molecules. Given the need to image aggrecan
from tissue-engineered construct samples, which may contain low amounts of aggrecan, an
important objective in this study was to find the minimum working conditions during
aggrecan sample preparation that would yield good AFM images. Improving the imaging
protocol in terms of some key instrument parameters and detailing the subsequent image
processing methods were also significant objectives in this study.
The sample preparation conditions needed to immobilize aggrecan on the APTES-mica
surface for subsequent imaging were optimized. After slightly testing the range of the
established sample preparation conditions using fetal bovine epiphyseal aggrecan, a more
driven test was conducted to find the minimum concentration at which aggrecan solutions
could be used for sample preparation and subsequent AFM imaging. These experiments
indicate that a minimum of 25 ptg/mL of aggrecan should be used to ensure representative
images of the aggrecan molecules. Since a very low concentration of aggrecan is being
used, the incubation time must be on the longer side (e.g., one hour) to ensure attachment
of aggrecan molecules to the APTES-mica surface.
In addition, the range of instrument and software parameters relevant to tapping mode
AFM for imaging aggrecan molecules was explored. These include the integral and
proportional gains, which are values ranging from 0 to 1 used to maintain constant
amplitude for tapping mode, and the resolution, which is proportional to the size of the
image field. Imaging studies showed that the optimal working range of the integral and
proportional gains was 0.2 - 0.4 and 0.6 - 0.8, respectively. One must always strike a
balance when controlling these and other parameters to keep the force with which the tip
traces the surface of the sample high enough to provide accurate surface contour but low
enough to prevent noise, as well as damage to the sample surface and the tip itself.
The resolution was increased to show imaging fields at the 800 nm level, as opposed to the
default 2 ptm level, while maintaining visibility of the desired structural details of the
aggrecan molecules. It may be possible to enhance the resolution to get a more detailed
view at the single-molecule level by finding ways to minimize noise, such as by suspending
the NanoScope Ila Multimode AFM mid-air via a tripod and improving the stability of the
cantilever and tip holder. Special care must be taken when setting up the microscope for
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imaging to make sure that the microscope head, the cantilever holder, the tip or probe, and
other relevant equipment is stabilized and set up properly.
This study was very useful in establishing a thorough protocol for sample preparation
relevant to aggrecan molecules, as well as subsequent AFM imaging and, particularly,
image processing. The established procedures can be used to look at aggrecan from native
cartilage and tissue-engineered constructs so that we can learn more about this molecule
and how it is affected by different experimental conditions.
Finally, the approach taken to develop this AFM imaging assay can be refined for other
relevant molecules in the cartilage ECM with the ultimate goal of broadening our
understanding of osteoarthritis and developing treatment strategies. It may be interesting
to observe the key players in the ECM both individually and as they interact with each
other to perform their structural and functional roles.
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3.5 Figures
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Figure 3.1 Aggrecan Imaging Using AFM Tapping Mode. (A) Aggrecan molecules can be
immobilized on the APTES-mica substrate in a flattened conformation and imaged by a sharp silicon
probe tip [3.15]. (B) Image of newborn human aggrecan (250 ptg/mL incubated for 30 min).
B. C.
Laser aiming screws
Laser reflection window
(photodetector not shown)
Mirror adjustment screws
Adjustable detector mirror
Sample
Figure 3.2 NanoScope 1I1a Multimode AFM. (A) Piezo connected to the equipment controller. (B)
Microscope head and cantilever holders. (C) Manufacturer schematic of the inner workings of the
microscope head with a cantilever holder.
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Figure 3.3 Image Processing Heuristic. A sample of fetal bovine epiphyseal aggrecan at a
concentration of 50 pg/mL can be seen in three consecutive stages of image processing.
250 p.g/mL 200 pg/mL
20 min 40 min 20 min 40 min
Figure 3.4 Test of Established Conditions for Sample Preparation. An initial test of the range of
the established sample preparation conditions (i.e., 250 [ig/mL of aggrecan incubated for 40
minutes) was conducted by preparing samples with variations in concentration and incubation time.
25 ug/mL 50 [tg/mL
Figure 3.5 Minimization of Aggrecan Concentration Needed During Sample Preparation.
Given that samples from tissue-engineered constructs usually yield low amounts of aggrecan, there is
an interest in finding the minimum concentration of aggrecan that will yield good AFM images.
Results indicate that samples should be prepared at no less than 25 ptg/mL of aggrecan to ensure
representative images of the molecules. Aggrecan molecules tend to curl at low concentrations, as
seen in the left panel.
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Figure 3.6 Integral and Proportional Gains During AFM Imaging. Images of the same sample
section were captured while varying the integral and proportional gains to find the optimal
combination of these parameters when dealing with aggrecan molecules. Results indicate that the
best working ranges for the integral gain (IG) and proportional gain (PG) are 0.2-0.4 and 0.6-0.8,
respectively. Higher-quality images in this figure are (1) IG 0.4 PG 0.5, (2) IG 0.3 PG 0.6, (3) IG 0.3 PG
0.7, (4) IG 0.4 PG 0.7, (5) IG 0.3 PG 0.8, and (6) IG 0.4 PG 0.8, which are outlined in black.
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Figure 3.7 Integral and Proportional Gains During AFM Imaging. Images of the same sample
section were captured while varying the integral and proportional gains to find the optimal
combination of these parameters when dealing with aggrecan molecules. Results indicate that the
best working ranges for the integral gain (IG) and proportional gain (PG) are 0.2-0.4 and 0.6-0.8,
respectively. Higher-quality images in this figure are (1) IG 0.3 PG 0.6, (2) IG 0.3 PG 0.7, (3) IG 0.4 PG
0.7, and (4) IG 0.2 PG 0.8, which are outlined in black.
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Figure 3.8 Image Resolution During AFM Imaging. Images of the same sample section were
captured while at different resolutions to find the best image while preventing distortion and noise.
Results indicate that the resolution can be increased to show imaging fields at the 800 nm level with
minimal noise. For Field 1, the integral gain was 0.3 and the proportional gain was 0.6. For Field 2,
the integral gain was 0.2 and the proportional gain was 0.8.
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Chapter 4: Summary and Conclusions
Affecting over 27 million people in the United States alone, osteoarthritis (OA) is a
degenerative joint disease caused by the progressive deterioration of cartilage tissue in
joints. Unfortunately, there is no cure for OA and current treatments are not enough to
fully alleviate disease symptoms which can have a profound impact on the health and
everyday activities of affected patients. Thus, there is a drive among the research
community to develop alternative therapies for this disease.
Tissue engineering principles can be applied to develop therapeutic techniques for OA.
Materials such as agarose and self-assembling peptides have been used to make hydrogels
for in vitro culture of bovine bone marrow stromal cells (BMSCs) which can differentiate
into chondrocytes and undergo chondrogenesis to produce cartilage tissue. Prior to the
experiment documented in Chapter 2, the differences in cell morphology that characterize
chondrogenesis had been observed in peptide hydrogels such as KLD and RAD but not in
the 2.0% agarose hydrogels typically used for culture.
A tissue engineering study was conducted to determine if a suitable environment for cell
proliferation and differentiation could be obtained using different agarose compositions, or
if self-assembling peptides are more favorable scaffolds. BMSCs were cultured in 0.5%,
1.0%, and 2.0% agarose hydrogels for a period of 21 days following TGF-p1
supplementation. Results from a variety of experiments such as the Live-Dead Imaging
Assay, the GAG Assay, the DNA Assay, and the Radiolabel Incorporation Assay indicate that
the 0.5% agarose hydrogels are clearly inferior scaffolds when compared to the 1.0% and
2.0% agarose hydrogels, which are generally comparable. Since agarose gels appear to be
suboptimal in promoting chondrogenesis, self-assembling peptides should be used in
future studies.
A main concern when developing cartilage-replacement treatments is ensuring that tissue-
engineered constructs possess the same properties as native cartilage tissue. As described
in Chapter 3, atomic force microscopy (AFM) can be used to image key molecules in this
tissue to help in developing treatments based on tissue engineering techniques. Aggrecan,
a molecule intrinsic to cartilage, was used as a model to develop an AFM imaging assay
useful for cartilage tissue engineering. The assay includes a sample preparation stage,
manipulation of instrument and software parameters, and an image processing protocol.
Fetal bovine epiphyseal aggrecan was used to optimize the sample preparation conditions
such as the concentration and incubation time needed to create the aggrecan monolayer on
a mica surface for imaging, especially since the 250 tg/mL concentration previously used
would require excessive amounts of sample materials. AFM imaging experiments were
conducted with 10, 25, and 50 ptg/mL of aggrecan while using a 60 min incubation period.
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Results indicate that aggrecan samples should be prepared at no less than 25 pg/mL to
ensure representative images of the molecules. Next, the instrument and software
parameters were optimized by focusing on finding the working range of the integral and
proportional gains (0.2 - 0.4 and 0.6 - 0.8, respectively) and by increasing the resolution to
show imaging fields at the 800 nm level as opposed to the 2 ptm level previously used in
similar experiments in our lab. Finally, an image processing protocol relevant to these
molecules was established. The resulting protocols for sample preparation, AFM imaging,
and image processing have been included with thorough details in Appendix A.11. It is
important to note that the approach taken to develop the aforementioned AFM imaging
assay could be refined for other molecules relevant to cartilage with the ultimate goal of
broadening our understanding of osteoarthritis and developing treatment strategies.
Though it was not detailed in this thesis, another project of mine was to use the AFM
Imaging Assay for Aggrecan to explore samples of tissue-engineered constructs. These
consisted of BMSCs enclosed in RAD peptide, with and without dexamethasone.
Unfortunately, only very low volumes (i.e., -50 ptL) of these samples were available at
nominal aggrecan concentrations and initial images proved that more aggressive sample
purification measures were needed to obtain the purity required for effective aggrecan
imaging. An aggrecan extraction protocol using cesium chloride density centrifugation had
been used in the past with about ten times the starting sample volume, with nominal
aggrecan concentrations. Pilot tests using readily-available native cartilage were
conducted to see if the extraction protocol would work for our low-volume samples.
Results indicated that the protocol could not be satisfactorily altered to accommodate for
low-volume samples, so images from the available samples of BMSCs enclosed in RAD
peptide could not be obtained. Still, details on how to effectively carry out the aggrecan
extraction protocol were established and updated procedures can be found in Appendix
A.10. This protocol should be used to effectively extract and purify aggrecan from tissue-
engineered constructs in preparation for AFM imaging.
The in vitro work discussed in this thesis is only a part of the greater efforts in the field of
cartilage tissue engineering. This exciting area continues to thrive with creative studies
pursuing goals like improving cell culture techniques, testing the effect of multiple
cytokines on constructs, binding particular molecules for enhanced functionality,
comparing different matrices or scaffolds, among others. Given that numerous challenges
are associated with the application of engineered tissues as reliable and effective
treatments in vivo, collaborative animal studies that test the potential of these therapeutic
systems in veterinary and, eventually, human therapy should be conducted. Using in vitro
studies helps to further our knowledge of OA and provides a foundation for designing in
vivo studies to find promising technology for cartilage repair and regeneration.
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Appendix
A.1 Isolation and Expansion of BMSC's
Objective:
Isolate bone marrow stromal cells (BMSCs) from the femoral and tibial diaphyses of bovine
calf joints. Expand the isolated cells and culture or cryporeserve for future experiments.
Procedure:
Bone Marrow Harvest and Processing
Materials:
e Bovine calf joints (Research 87, Marlborough, MA)
e 50 mL Falcon conical tubes, two for each bone to be harvested
e PBS1X
e PSA (100 U/mL penicillin, 100 ptg/mL streptomycin, and 250 ng/mL amphotericin)
* 70% Ethanol
e Sterilized carving knife and hand-saw blade
e Sterilized forceps and scoop spatulas
e 25 mL and 5 mL pipettes
e 16-gauge and 18-gauge needles
e 70 ptm cell strainers
1) Prepare a 50mL Falcon conical tube with 25 mL PBS and 1% PSA for each bone to be
harvested.
2) Remove all the connective tissue and muscle around the mid-diaphysis of each bone
using a sterilized carving knife.
3) Clean the bone with 70% ethanol.
4) Cut the bone at the mid-diaphysis with a sterilized hand-saw blade and transfer to the
tissue culture hood.
5) Carefully remove the bone marrow from the medullary cavity with a forceps and a
scoop spatula and transfer it to the prepared 50mL conical tubes with PBS and 1% PSA.
(Note: Avoid scraping the interior surface of the bone to preserve the purity of the
extracted bone marrow.)
6) Break up the bone marrow through vigorous pipetting using a 25 mL followed by a 5mL
pipette. Mechanical disruption through subsequently smaller pipettes helps unravel
the large pieces. (Note: You may also need to use a syringe without a needle attached
to apply enough pressure.)
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7) Continue to homogenize the bone marrow by passing the material through a 16-gauge
needle.
8) Centrifuge the homogenized bone marrow at 1000 g for 15 minutes.
9) Carefully aspirate the supernatant and the fatty layer. Discard these materials.
10)Resuspend the cell pellet in fresh PBS. Mix well.
11)Pass the cell suspension through an 18-gauge needle and then through a 70 Im cell
strainer onto a new 50 mL Falcon conical tube.
Nucleated Cell Count and Cell Plating
Materials:
e Cell suspension in 50 mL Falcon conical tubes
e Ammonium Chloride-Tris Base (7.6 mg/mL Ammonium Chloride, 2.4 mg/mL Tris Base)
e Eppendorf 0.5 mL microcentrifuge tubes for cell counting dilutions
e Pipettes and micropipettes with sterile tips
e Hemocytometer for cell counts under light microscope
e BMSC Expansion Medium (LG-DMEM with 10% ES-FBS, 1% HEPES, and 1% PSA)
e bFGF stock solution (25 ng/ tL) from freezer (R&D Systems, Minneapolis, MN)
e 0.05% Trypsin-EDTA
e T-flasks for culture as needed
1) Prepare a 1:20 dilution of the cell suspension in Ammonium Chloride-Tris Base for
nucleated cell count in an Eppendorf 0.5 mL microcentrifuge tube.
Note: Dilutions may need to be adjusted for each harvest depending on the cell density
of the suspension.
2) Obtain the approximate nucleated cell count via the Trypan Blue exclusion method
using a hemocytometer.
3) Centrifuge the cell suspension at 200 g for 15 minutes.
4) Aspirate the supernatant and resuspend the cell pellet in BMSC Expansion Medium with
1 ng/mL FGF.
5) Pre-plate approximately 75 x 106 cells in 5mL on 100 mm tissue culture treated petri
dishes.
6) Incubate for 30 minutes to allow rapidly-adhering cells to attach.
7) Transfer the media and non-adherent cells to a T-flask and add another 10mL of BMSC
Expansion Medium (approximately 1 x 106 cells/cm 2 in 15 mL media; - 75 x 10 6/T-75).
8) After 2 days in culture, aspirate out the media and add fresh BMSC Expansion Medium.
9) Continue to culture flasks until cells are nearly (75-80%) confluent [P0].
10)Remove the cells that have adhered to the T-flask wall with 0.05% trypsin-EDTA.
11)Centrifuge at 200 g for 15 minutes and resuspend in PBS.
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12)Obtain the approximate nucleated cell count via the Trypan Blue exclusion method
using a hemocytometer.
13) If you want to cryopreserve the cells for future experiments, freeze them in aliquots of 5
million cells/vial using liquid nitrogen. Make sure to use appropriate freeze tubes and
don't tighten the caps too much.
14)If you want to culture the cells immediately, re-plate at approximately 6,000 cells/cm 2.
15)Culture until 60-70% confluent (2-3 days), passage [P1], and reseed again at 6,000
cells/cm 2.
16)Culture again until 60-70% confluent (2-3 days), passage [P2], and seed into 3-D
constructs for chondrogenesis.
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A.2 Thaw and Expansion of Cryopreserved BMSC's
Objective:
Thaw and expand cryopreserved bovine bone marrow stromal cells (BMSCs) for
experimental use.
Procedure:
Thawing Cells and Seeding Flasks
Materials:
* Vial with cryopreserved cells from liquid nitrogen tank
* HG-DMEM (4.5 g/L glucose) from refrigerator
e BMSC Expansion Medium from refrigerator
* FGF stock solution (25 ng/ptL) from freezer
e Falcon conical tube (15 mL)
e Pipettes and micropipettes with sterile tips
" Hemocytometer for cell counts under light microscope
* Bottle for Seed Medium
e T-185 culture flasks
1) Make BMSC Expansion Medium (LG-DMEM with 10% ES-FBS, 1% HEPES, and 1% PSA)
according to "MSC Media Calcs" spreadsheet.
2) Remove desired vial of BMSCs from the cryopreservation chamber. Quickly loosen the
cap to keep the vial from exploding due to rapid changes in temperature.
3) Thaw the vial of BMSCs as quickly as possible by dipping it in the 370 C water bath and
shaking vigorously.
4) Resuspend the cells in 10 mL of HG-DMEM in a 15 mL Falcon conical tube.
5) Spin down cells at 200 g (200 rcf) for 8 min using the centrifuge in the Zhang Lab. Make
sure to take a Falcon tube with 10 mL of water to use as a counterbalance.
6) Carefully aspirate the supernatant through the vacuum to leave the cell pellet at the
bottom of the tube.
7) Resuspend the cells in 5 mL of BMSC Expansion Medium. Mix well by using the 1000 pL
micropipette.
8) Count cells using the hemocytometer and determine the following using the "BMSC
Thaw" spreadsheet:
Note: Each T-185 will have 25 mL of Seed Medium (BMSC Expansion Medium with cells
and FGF)
e Amount of T-185 flasks to seed (usually 4 flasks)
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o Input: Cell count (viable cells using Trypan Blue), total volume (- 5 mL),
dilution factor (2)
o Output: #T-185s
" Amount of FGF solution needed in Seed Medium for 5 ng/mL FGF
lasks x 25 mL Seed Media 5 ng FGF XpL FGF soln =_ L FGF soln
flask mL Seed Media 25 ng FGF -- ~~~~~
" Amount of cell suspension needed in Seed Medium for 6000 cells/cm 2 in the T-185s
f lasks x mL cell suspension - ___ mL cell suspension
* Amount of BMSC Expansion Medium needed in Seed Medium
f lasks X 25mL Seed Media mL cell suspension = _ mL BMSC Exp Med
9) Make Seed Medium using the calculated amounts of BMSC Expansion Medium, FGF
solution, and cell suspension. Mix well by pipetting up and down.
10)Add 25 mL of Seed Medium to the culture-treated side of each T-flask. Be careful not to
get any media on the mouth of the flasks to prevent growth in that area.
11)Place the T-flasks in the incubator at 37*C. Make sure the culture-treated sides are
facing down and that the liquid is level throughout the flasks. Don't stack more than 2-3
flasks on top of each other.
12) Leave the flasks in the incubator for 3 days before passaging cells for further expansion.
Passage Cells (3 Days After Seeding)
Materials:
e T-185 culture flasks from incubator
* PBS IX from refrigerator
e Trypsin from freezer
e FBS Medium from refrigerator
e FGF stock solution (25 ng/pL) from freezer
e Pipettes and micropipettes with sterile tips
e Hemocytometer for cell counts under microscope
e Bottle for Passage Medium
* T-185 culture flasks
1) Remove the Seed Medium from the T-flasks by aspirating through the vacuum.
2) Add 10 mL of PBS to the culture-treated side of each T-flask.
3) Wash by aspirating with a pipette and rinsing the culture-treated side of each T-flask 2-
3 times.
4) Remove the PBS from the T-flasks by aspirating through the vacuum.
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5) Add 2 mL of trypsin to each T-flask. Lay down the flasks and tilt them to make sure that
the entire surface is covered in trypsin. Place the flasks in the incubator at 370 C for 4
min.
6) Add 8 mL of FBS Medium to each T-flask to inactivate the trypsin. Wash by aspirating
with a pipette and rinsing the culture-treated side of each T-flask 2-3 times.
7) Combine the media from all flasks into one T-flask.
8) Count cells using the hemocytometer and determine the following using the "BMSC
Thaw" spreadsheet:
Note: Each T-185 will have 25 mL of Passage Medium (FBS Medium with cells and FGF)
" Amount of T-185 flasks to seed (usually 15 flasks)
o Input: Cell count (viable cells using Trypan Blue), total volume (- 3-4 mL),
dilution factor (20)
o Output: # T-185s
* Amount of FGF solution needed in Passage Medium for 5 ng/mL FGF
flasks x 25 mL Passage Media 5 ng FGF piL FGF soln = L FGF Solnf lask mL Passage Media 25 ng FGF -
* Amount of cell suspension needed in Passage Medium for 6000 cells/cm 2 in the T-
185s
flasks x llss . _ mL cell suspension
e Amount of FBS Medium needed in Passage Medium
flasks x 25mL Passage Media - ____ mL cell suspension = _ mL FBS Mediumf lask
9) Make Passage Medium using the calculated amounts of FBS Medium, FGF solution, and
cell suspension. Mix well by pipetting up and down.
10)Add 25 mL of Passage Medium to the culture-treated side of each T-flask. Be careful not
to get any media on the mouth of the flasks to prevent growth in that area.
11)Place the T-flasks in the incubator at 370 C. Make sure the culture-treated sides are
facing down and that the liquid is level throughout the flasks. Don't stack more than 2-3
flasks on top of each other.
12)Leave the flasks in the incubator for 3 days and prepare for casting.
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A.3 Encapsulation of BMSC's in Hydrogels
Objective:
Prepare agarose rings using custom molds for BMSC encapsulation. Cast BMSC-seeded
hydrogels for cell culture. Hydrogels can be agarose or self-assembling peptides such as
RAD and KLD.
Procedure:
Casting Acellular Agarose Rings
Materials:
* Custom 3-piece casting mold (Ring, Cap, Post)
* 2% LMP Agarose (or stock 3% LMP Agarose, Invitrogen) from refrigerator
* 24-well non-tissue culture treated plates
* Repeater pipette (beige Eppendorf)
* 1.25 mL sterile, individually-wrapped repeater pipette tips
* 1X PBS without Ca2+ or Mg2 +, sterile, pH=7.2 from refrigerator
1) Autoclave the following materials on the dry cycle for 20 min:
* Agarose ring molds (metal rings, metal caps, and white center posts in separate
beakers)
" Spatula with thin tip
" Tweezers with long tips
e Tweezers with grip
2) Sterilize the 3% agarose stock by autoclaving on the wet cycle for 20 min.
3) Prepare 2% agarose solution based on the calculations below. Mix well by pipetting up
and down and leave the solution in the water bath at 66'C so that it stays melted.
Notes: Melt agarose by placing it in a water bath at 66'C. Refrigerate agarose to solidify
for storage. Each 24-well plate requires -3mL of 2% agarose for making all the rings.
* Amount of 2% agarose needed for the desired number of rings
rings x 0.12 5 mL 2% agarose = ____ mL 2% agarose
* Amount of 3% agarose needed to make the desired 2% agarose
___ mL 2% agarose x 2% _Ag mL 3% agarose3%Ag
* Amount of PBS to add to the 3% agarose to make the desired 2% agarose
mL 2% agarose - mL 3% agarose - = ___ mL PBS
4) Assemble casting molds in 24-well plates. Use the tweezers to align the pieces
correctly.
* Place metal rings with the smooth side facing up using tweezers with long tips.
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e Place metal caps with the smooth side facing down using tweezers with long tips.
* Align the holes of the rings and caps such that the 2% agarose poured through the
holes leaks into the space in between the metal parts to form the rings.
e Place the white posts in the center of the rings and check their stability using the
tweezers with grip.
5) Add 125 p.L of 2% agarose to each ring through the holes of the metal caps using a
repeater pipette.
Notes: Repeater pipette (beige Eppendorf) should be set at 5 for 125 ptL. The pipette
allows casting of 8 rings per full tip. Before discharging the first 125 p.L dose, discharge
a 25 [tL dose (set at 1).
6) Refrigerate the plate for at least 5 min so that the agarose rings can solidify.
7) Remove the molds carefully and aspirate excess agarose from the center or
surroundings of the rings.
8) Add PBS to wells (enough to cover the rings) and store in the refrigerator at 4C for up
to 4 days.
Note: Make sure to complete the agarose rings 1-2 days prior to BMSC trypsinization
during casting.
Casting Cells in Agarose Rings (2 Person Procedure)
Materials:
e 24-well non-tissue culture treated plates with 2% agarose rings
e Casting Medium: HG-DMEM with 25mM HEPES, 1% ITS+1, 1% NEAA, 1% Na Pyr, 1%
PSA, and 0.4% Proline
e Culture Medium: HG-DMEM with 10mM HEPES, 1% ITS+1, 1% NEAA, 1% Na Pyr, 1%
PSA, and 0.4% Proline
e FBS Medium: LG-DMEM with 10mM HEPES, 10% ES-FBS, and 1% PSA
e 1X PBS, sterile, pH=7.2
* 0.05% Trypsin/EDTA
a 10% Sucrose, Sterile
e 10% Sucrose, Sterile with 2.5mM HEPES
e Desired hydrogel solution for cell encapsulation
a) 2% LMP Agarose (or stock 3% LMP Agarose, Invitrogen) from refrigerator
b) Peptide powder, sterile
Example: For 0.35% KLD12, you need 1.5mL x 3.5mg/mL x 1.2 = 6.3 mg/cast.
e 2mL screw top tubes, sterile
e 5mL polypropylene snap top tubes, sterile (BD Falcon)
e Repeater pipette
e 1.25 mL sterile individually wrapped repeater pipette tips
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1) Aspirate PBS from each agarose ring and clean up loose agarose debris.
2) Add -0.5mL of Casting Medium (above) to each well.
3) Place plate(s) in 37'C incubator.
4) Prepare hydrogel solutions for cell encapsulation:
a) For agarose hydrogels, dissolve the stock agarose solution to the desired
concentration in sterile 10% sucrose by vortexing and sonicating. Leave the
solution in the water bath at 42C to prevent solidification of the agarose.
b) For peptide hydrogels, dissolve the peptide at 4.375 mg/mL (for 3.5 mg/mL final
concentration) in sterile 10% sucrose by vortexing & sonicating. Leave the peptide
solution in the sonicator.
5) Trypsinize cells and inactivate with FBS Medium.
6) Centrifuge cells and resuspend in FBS Medium at > 10 x 106 cells/mL. Estimate this
count based on the previous passage yield.
7) Count cells via the Trypan Blue exclusion method using a hemocytometer.
8) Aliquot 15 x 106 cells into 2 mL sterile screw top tubes. Store tubes at 4C.
9) Prepare 5 mL tubes with 1.2 mL of the prepared hydrogel solutions. Return the tubes
to the water bath or sonicator as appropriate.
10)Centrifuge desired 2 mL tubes with 15 x 106 cells at 100 g for 5 minutes.
11)While spinning, aspirate the media out of 23 acellular agarose rings in the 24-well plate,
leaving the center of each ring dry. (Only 23 rings will be cast with cell-seeded
hydrogels due to repeater pipette limitations.)
12)Assemble a repeater pipette with 1.0 mL or 1.25 mL tip and set it to 50 [1L.
13)Person #1: Aspirate media from the 2 mL tubes and resuspend the cell pellet in 300 pL
of sterile 10% sucrose with 2.5mM HEPES.
14)Person #2: Hold the 5 mL tubes with 1.2 mL of prepared hydrogel solutions.
15)Person #1: Inject the cell suspension into the 5 mL tube with the desired hydrogel.
16)Complete the following in 60 seconds, starting from the time the cells are added to the
hydrogel solution: (Speed is of the essence to prevent solidification prior to casting.)
a) Gently vortex the cell-seeded hydrogel suspension to ensure homogeneous cell
distribution.
b) Gently draw the cell-seeded hydrogel suspension into the repeater pipette. Make
sure to avoid bubbles.
c) Rapidly, but gently, dispense 50 ptL of the cell-seeded hydrogel suspension into the
center of up to 23 agarose rings.
17)Wait at least 5 minutes and add 300 p.L of Casting Medium to each well, making sure the
tops of the hydrogel disks are covered.
18)Aspirate the Casting Medium from each agarose ring while taking care of not damaging
the ring or hydrogel disks.
19)Add 750 ptL of Culture Medium to each well.
20)Incubate at 370 C.
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A.4 Cell Culture Media Changes and Sampling
Cell Culture Media Changes
Objective:
Change the cell culture media every 2-3 days to promote growth during extended periods.
Procedure:
Materials:
e Cell culture media stock from refrigerator shelf
* Media supplements from freezer (e.g. A2P + Dex)
e Falcon tube for required media
e Pipettes and Micropipettes
* Labeled mini tubes for saving media from gels
e Waste container
e Culture plates from incubator
Preparation of Culture Media
1) Calculate the amount of media required for the gels that need a media change.
gels x O.750mL media = ____ mL media
2) Use the "MSC Media Calcs" spreadsheet to determine the amount of media supplements
that must be added to the required media.
mL A2P + Dex
3) Sterilize hood in Tissue Engineering Lab by wiping with 70% ethanol.
4) Transfer the amount of required media to a Falcon tube using an appropriate pipette.
5) Add the calculated amounts of media supplements to the Falcon tube using appropriate
micropipettes.
Media Change
1) Sterilize hood in Tissue Engineering Lab by wiping with 70% ethanol.
2) Use a 1000 p.L micropipette to aspirate old cell culture media out of each well in the
culture plates and into the corresponding labeled mini tube for saved media. Dispose of
undesired media in the waste container.
3) Add 750 ptL of new cell culture media to the desired wells in the culture plates.
4) Place the culture plates back in the incubator at 37'C and freeze the saved media from
the gels at -20'C.
5) Empty the waste container in the hood's vacuum waste system.
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Cell Culture Sampling
Objective:
Obtain sample plugs from tissue culture plates for different assays.
Procedure:
Materials:
e Freezer vials (2mL) and tube rack for samples
e Bent spatula and pointed spatula
e Burner and igniter for sterilization
e Culture plates from incubator
1) Sterilize hood in Tissue Engineering Lab by wiping with 70% ethanol.
2) Sterilize bent and pointed spatulas by spraying them with 70% ethanol and then
flaming over the burner.
3) Remove agarose rings from desired plugs and place them in their corresponding freezer
vials.
Method 1: Use the pointed spatula to gently tap the edges of the ring and detach it from
the well. Use the bent spatula to lift the edge of the ring slightly and release it. The fluid
motion should allow the plug to float out of the ring. Remove the ring from the well
using the pointed spatula and carefully place the plug in the desired vial using the bent
spatula.
Method 2: Use the bent spatula to remove both the ring and the plug from the well and
place them on a petri dish. Use the pointed spatula to carefully cut the ring and detach
it from the plug. Place the plug in the desired vial using the bent spatula.
4) Place the culture plates back in the incubator.
5) Store the freezer vials in the Wet Lab freezer for future assays.
6) Discard the detached agarose rings in the hood's vacuum waste system.
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A.5 Live-Dead Imaging Assay
Objective:
Image sample plugs during cell culture to obtain a qualitative picture of cell viability. Using
the dyes listed below, live cells will appear green and dead cells will appear red. Cell
morphology may also be explored.
Procedure:
Microscope Setup
1) Go to Microscope Room and check the logbook. If the mercury lamp is off, make sure it
has been off for at least 30 min before turning it on. If it is on, fill in the logbook and
proceed with your work.
2) Turn on the mercury lamp (3rd switch box) and wait 30 min before imaging any
samples.
Note: Make sure that the other three switches are off, since turning them on before the
mercury lamp could cause voltage issues and damage the equipment.
Preparation of Samples
Materials:
* PBS 1X from refrigerator
* Microscope slide with 4 wells
e Bent spatula and pointed spatula
e Micropipette (1000 ptL)
* Burner and igniter for sterilization
e Culture plates from incubator
1) Sterilize hood in Tissue Engineering Lab by wiping with 70% ethanol
2) Sterilize bent and pointed spatulas by spraying them with 70% ethanol and then
flaming over the burner.
3) Remove agarose rings from desired plugs and place them in the microscope slide with 4
wells.
Method 1: Use the pointed spatula to gently tap the edges of the ring and detach it from
the well. Use the bent spatula to lift the edge of the ring slightly and release it. The fluid
motion should allow the plug to float out of the ring. Remove the ring from the well
using the pointed spatula and carefully place the plug in the microscope slide using the
bent spatula.
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Method 2: Use the bent spatula to remove both the ring and the plug from the well and
place them on a petri dish. Use the pointed spatula to carefully cut the ring and detach
it from the plug. Place the plug in the microscope slide using the bent spatula.
4) Add 1mL of PBS to plugs in the microscope slide.
5) Place the culture plates back in the incubator.
6) Discard the detached agarose rings in the hood's vacuum waste system.
Live/Dead Imaging
Materials:
e Microscope slide with 4 wells
e Fluorescent dyes (Red and Green) from refrigerator
- Ethidium bromide (Red), 350 ng/mL, for dead cells
- Fluorescein diacetate (Green), 12.5 pg/mL, for live cells
e White box next to the sink in the Tissue Engineering Lab with:
- Tips for micropipettes
- Radioactive tip disposal box
- Liquid waste container
- Micropipettes from Wet Lab
e Nikon Eclipse Fluorescent Microscope
1) After the 30 min wait for the mercury lamp to warm up, go to the Microscope Room and
turn on the microscope using the other three switches.
2) Setup the software (Openlab 4.0.4) for imaging.
3) Add dyes to the first sample and mix with 1000 ptL pipette by gently aspirating up and
down.
a. 0.35 ptL of red dye to stain nuclei (dead)
b. 0.10 ptL of green dye to stain cytoplasm (live)
4) Remove the dye solution with the pipette while making sure that the plug remains
around the center of the well. This will allow better visibility under the microscope.
5) Place under the objective (set to 1OX, Phase 1) and turn on UV lamp (upper left button
on the control panel). Move the filter switch LEFT to view green dye and RIGHT to view
red dye. Keep the white light in the microscope and the room light off, since the dyes
can photobleach.
6) Capture images using the Auto Exposure button (AE) and then the Camera button.
Repeat for a total of 3 fields per plug, making sure that the fields are representative of
what is observed in the plugs.
7) Color the images by going to "Enhance Image" and selecting green or red, depending on
the filter being used for the desired field. Also, go to "Enhance Contrast"
(Image>Contrast>Best Guess>OK).
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8) Merge green and red images by selecting both files (hold Shift key) and dragging them
to "New."
9) To save all images as TIFS, select them in blue and then go to Image>Depth>Millions of
Colors>Selected Layer>OK. Then go to File>Save as Multiple>Naming>Start with
Document Name & Append a Numerical Subscript. Finally, save to my file and copy to
my USB flash drive. To remove the USB flash drive, go to File>Eject "No Name." (If this
is not done, the files will not copy.)
10)Turn off the last three switches of the microscope and then the Mercury lamp. (Turning
off the Mercury lamp first could cause voltage issues and damage the equipment.)
Record the time in the logbook.
11) Dispose of samples by aspirating them out of the wells with a pipette and placing them
in the liquid waste container. Its contents can then be discarded in the vacuums under
the hoods.
12)Return all pipettes, tips, and white box to their appropriate places.
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A.6 Lyophilization and Proteinase K Digestion
Objective:
Lyophilize samples to dry and obtain final weights. Digest samples with Proteinase K so
that specific biomolecules can be detected by appropriate assays (e.g., GAG, DNA, radiolabel
incorporation).
Procedure:
Lyophilization
Materials:
* Pre-weighed red-cap freezer tubes containing hydrogel samples
e Box for placing sample vials in the lyophilizer, can be plastic or cardboard
1) Verify if the lyophilizer's lid is placed correctly over the refrigerator coil. Turn on the
machine.
2) Set the temperature using the "Manual" button and wait until it reaches the lowest
point in curve displayed on the lyophilizer.
3) Prepare the samples by loosening the caps of the tubes. Make sure they are still tight
enough to stay on the vials when the vacuum is applied.
4) Set them on the lyophilizer's sample chamber inside a box. Keep the box open.
5) Press the "Vacuum" button to start the vacuum and wait 2 hours while the samples
undergo the freeze-drying process.
6) After 2 hours, release the valve at the bottom of the machine to let the vacuum air out.
Be careful not to do this too quickly, since samples could be damaged.
7) Remove samples and turn off the lyophilizer.
8) Weigh the vials again to obtain the lyophilized weight of each hydrogel sample by
subtracting the weights of the empty tubes.
Note: Don't lyophilize the Day 0 samples or the radiolabel standards.
Proteinase K Digestion
Materials:
e Tris Buffer (50 mM Tris, 1 mM CaCl2, pH = 8.0, Sterile), stored in refrigerator
* ProK (5 mg/mL Proteinase K, recombinant PCR Grade, Roche Applied Science), stored
at 2-8'C freezer
e Box with red-cap freezer tubes containing lyophilized hydrogel samples
e Day 0 sample vials
1) Set the water bath in the Injury Room to 66'C and the oven in the back of the Wet Lab to
60'C. Check the temperatures periodically to ensure they reach appropriate levels.
2) After lyophilization, add 0.95 mL Tris Buffer to each hydrogel sample tube.
3) Melt the agarose-containing hydrogel samples, as well as the Day 0 samples, by placing
the vials in the water bath at 66'C.
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4) Add 50 ptL of ProK to the samples and the Day 0 vials for a final concentration of 0.25
mg/mL Proteinase K.
5) Mix well by vortexing and shaking fervently.
6) Place the samples and Day 0 vials in the oven at 60'C overnight. Make sure the oven
does not reach 65'C given that Proteinase K denatures at this temperature.
7) Samples can then be frozen or used to perform desired assays.
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A.7 GAG Assay
Objective:
Determine the sulfated glycosaminoglycan (GAG) content in samples. The GAGs (CS6, CS4,
HS, KS) are stained using dymethylmethylene blue (DMMB) dye and chondroitin-6-sulfate
is used as a standard due to its prevalence in articular cartilage. Samples must be
previously lyophilized and digested using Proteinase K.
Procedure:
Materials:
e Samples from freezer
* GAG Standard from freezer
e Tris Buffer from refrigerator
e DMMB dye solution from bench
* Mini test tubes
e Clear 96-well plate
* Wet lab micropipettes, repeater pipette, and tips
* Maxy machine and software in Wet Lab
1) Prepare a map for the
standards and samples.
clear 96-well plate used in this assay. Have duplicates of
1 2 3 4 5 6 7 8 9 10 11 12
A Std Std100 100
B Std Std75 75
C Std Std50 50
Std StdD 25 25 ___
Std StdE 12.5 12.5
F Std Std
__ _ _ 100 50 ___ ___ ___ _ _ _ ___ ___ _ _ _ _ _ _ ___
G Std StdG 75 25
H Std 0 Std 0
2) Prepare GAG standard solutions in mini test tubes using the Tris buffer. Make sure to
vortex the GAG standard stock and to mix the standards well by repeatedly pipetting up
and down. These standards will be used to relate the GAG concentrations to the
instrument readings.
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GAG Standard Volume of GAG Volume of
Concentration Standard Stock Tris Buffer
(ptg/mL) (ptL) (ptL)
100 .80 720
75 60 740
50 40 760
25 20 780
12.5 10 790
Note: The buffer used to prepare the standards should be the same as the buffer used in
the samples being tested. Tris buffer is the most common but other buffers or cell
culture media could be used.
3) Turn on the Maxy machine so that it has time to warm up.
4) Add 20 ptL of each standard and sample according to the plate map. Make sure to vortex
all solutions right before adding them to ensure that they are well-mixed.
5) Add 200 ptL of DMMB dye into each well using a repeater pipette. Remove any bubbles
left over in wells and dry any minor spills if necessary.
6) Scan plate in the Maxy machine.
e Click on "Read Plate" while at 520 nm wavelength.
e Save results by copying to a text document.
7) Dispose of plate contents in appropriate waste containers and return materials.
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A.8 DNA Assay
Objective:
The DNA Assay uses bisbenzimidazole fluorescent dye Hoechst 33258 to stain DNA present
in experimental samples and obtain readings for data processing in terms of DNA
concentration (pg/mL). The interaction of Hoechst 33258 with DNA requires at least four
consecutive A-T base pairs, as well as dissociation of DNA from proteins of the
nucleoprotein complex. The former is satisfied by random chance, while the latter can be
accomplished by digestion with Proteinase K, papain, or by a high salt dye buffer. The
stability of the dye and dye-DNA complex is great enough that the fluorescence will
decrease by less than 5% over 2 hours after the initial mixing of the dye solution and the
digested plug.
Procedure:
Preparation of DNA Dye Solution
Materials:
e 1x TEN Buffer (10 mM Tris, 1 mM Na2EDTA, 0.1 M NaCl, pH = 7.4, Sterile)
Note: The 1x TEN Buffer contains Tris, a buffer needed to maintain the DNA Dye
Solution's pH given that the DNA Assay is sensitive to pH. EDTA serves as a chelating
agent by binding up free ions such as Mg2 +, which usually serve as co-enzymes for
DNAases, RNAases, and other degradation-type proteins.
e Hoechst 33258 Dye Solution (10,000x, Sterile)
Note: The Hoechst 33258 Dye Solution (10,000x, Sterile) is a stock solution of 1 mg/mL
Hoechst 33258 dye powder in sterile DI H20. Because it degrades from exposure to
light, the solution is kept in brown bottle at 4C. Stored like this, it should remain viable
for at least 6 months. Note that the final DNA Dye Solution will have a concentration of
0.1 ptg/mL Hoechst 33258 dye.
e DI H2 0, Sterile
e 50 mL Falcon conical tube
1) Prepare 1x TEN Buffer by adding 45 mL of DI H20 and 5 mL of 10x TEN Buffer into a
50mL conical tube. Mix well.
2) Prepare the DNA Dye Solution by adding 5 [tL of 1 mg/mL of Hoechst 33258 Dye
Solution into the 1x TEN Buffer in the 50 mL conical tube. Mix well.
Note: The DNA Dye Solution is simply a mixture of 1x TEN Buffer and Hoechst 33258
Dye Solution (10,000x). All buffers and solutions must be kept sterile, so use sterile
technique when handling these reagents.
3) Cover the 50 mL conical tube containing the DNA Dye Solution with aluminum foil to
prevent degradation from exposure to light.
Note: The DNA Dye Solution is a possible carcinogen so it should be handled and
disposed of with care (i.e., Organic Liquid Disposal Jar, or Rx DNA Dye Disposal Jar if
mixed with something radioactive. Both containers are located in NE47-365.).
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Preparation of DNA Standard Curve and Sample Readings
Materials:
e Samples from freezer
e DNA Stock (10 pg/mL)
e Tris Buffer from refrigerator
e DNA Dye Solution (0.1 ptg/mL Hoechst 33258 Dye)
e Mini test tubes
e Black 96-well plate (Microfluor 2, Thermo #7805 from VWR)
* Wet lab micropipettes, repeater pipette, and tips
e Victor machine and software in Wet Lab
1) Prepare a map for the
standards and samples.
black 96-well plate used in this assay. Have duplicates of
1 2 3 4 5 6 7 8 9 10 11 12
A
B
C
D
E
F
G
H
2) Prepare DNA standard solutions in mini test tubes using the amounts of DNA Stock and
Tris Buffer listed in the table below. Make sure to vortex the DNA Stock and to mix the
standards well by repeatedly pipetting up and down. These standards will be used to
relate the DNA concentrations to the instrument readings.
Standard Solution DNA Conc. (ptg/mL) DNA Stock (pL) Tris Buffer (pL)
1 10 0 200
2 5 100 100
3 4 80 120
4 3 60 140
5 2 40 160
6 1 20 180
7 0 0 200
3) Prepare DNA standard solutions in mini test tubes using the amounts of DNA Stock and
Tris Buffer listed in the table below. Make sure to vortex the DNA Stock and to mix the
standards well by repeatedly pipetting up and down. These standards will be used to
relate the DNA concentrations to the instrument readings.
4) Turn on the Victor machine so that it has time to warm up.
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5) Add 20 ptL of each standard and sample according to the plate map. Make sure to vortex
all solutions right before adding them to ensure that they are well-mixed.
6) Add 200 pL of DNA Dye Solution (0.1 pg/mL Hoechst 33258 Dye) into each well using a
repeater pipette as needed. Remove any bubbles left over in wells and dry any minor
spills if necessary.
7) Put the plate in the Victor machine and read the plate according to the instructions
posted on the machine.
8) Dispose of plate contents in appropriate waste containers and return materials.
For more detailed information, please refer to:
Kim YJ, Sah RL, Doong JY, Grodzinsky AJ. (1988) Fluorometric assay of DNA in cartilage
explants using Hoechst 33258. Analytical Biochemistry 174(1): 168-176.
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A.9 Radiolabel Incorporation Assay
Objective:
Depending on the radiolabel used, this assay can be used to quantify proteoglycan
synthesis (35S-Sulfate), protein synthesis (3H-Proline), or cell proliferation/DNA synthesis
(3H-Thymidine).
Procedure:
Radiolabeling Samples
Materials:
e Bottle for ITS Medium Stock (HG-DMEM with 1% ITS+1, 1% HEPES, 1% NEAA, 1% Na
Pyr, 1% PSA, 0.4% Proline, and 1% Ascorbate-2-Phosphate) for radiolabeling day
e Bottle for ITS Medium with radiolabels, mark with tape for radioactive materials (Rx
tape)
e Bottle for ITS Medium without radiolabels
* Tube for stock radiolabeled media where isotopes will be added
e Tubes for different media groups that are radiolabeled
e Tubes for different media groups that are not radiolabeled
e Two red-cap freezer tubes for radiolabel standards (35 S and 35s 3H), mark with Rx tape
e Micropipette (1000 pL) and sterile tips
e Box for discarding radiolabled pipette tips
e PBS 1X with 1% PSA for empty wells
* Stock isotope solutions (35 S and 3H) from locked refrigerator
e 24-well plate(s) with cell-seeded hydrogel samples
1) Calculate the amount of ITS Medium Stock needed for samples with and without
radiolabels. Include the volumes for the initial radiolabeling day and two media
changes. Determine how much ITS Medium will be separated for each sample group.
2) Make ITS Medium Stock and split it into two groups: ITS Medium with radiolabels and
ITS Medium without radiolabels.
Note: Do not split up the radiolabeling media into subgroups because then you need
standards for each subgroup and it gets hard to compare between them.
3) Make sure you have labeled the mini test tubes for saving media from gels and the two
red-cap freezer tubes for radiolabel standards.
4) Mark tubes and plates that will contain radiolabeled samples with Rx tape where
appropriate.
5) Use the Grodzinsky Lab "Calculation Sheet for Solutions" spreadsheet to determine the
volume of each isotope (35S and 3H) needed and note their associated radiation (kCi) for
lab records.
a) Check the logbook to see what label number/letter we are on and how much is left.
b) Make sure that the calibration date in the spreadsheet is correct.
c) Enter 0.75 mL per hydrogel disk and number disks that will be radiolabeled.
d) Enter 1 mL for the standards. (There are two standards: 3sS and 3s3H).
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e) Keep the concentrations of 35S and 3H at 5 and 10 pCi/mL, respectively.
f) Print the sheet of what you are using to keep for your records.
6) Remove your watch and other metal items when working with isotopes.
7) Remove the appropriate isotope vials from the locked refrigerator in the Tissue Culture
Room. Check the labels to make sure they match the logbook records. Note which label
you are using on the printed sheet.
8) Prepare the tissue culture hood with all necessary media bottles, tubes, and pipettes.
Note: Only use micropipette tips to handle isotope solutions or radiolabeled media. Do
not use 5 mL or 10 mL pipette tips because they are difficult to dispose of as radioactive
materials (e.g., large tips must be broken in half so they fit in our containers for
radioactive materials). Also, do not aspirate radiolabeled media into the regular media
waste container. This would make the entire waste solution a radioactive material with
specialized disposal needs.
9) The 35S isotope must be handled first. Add the calculated amount of 35S isotope to the
tube for stock radiolabeled media and mix well.
10)Transfer 1 mL of the media at this time for the 35 standard to the appropriate red-cap
freezer tube. If you forget to do this, you must start over.
Note: Be extraordinarily careful not to spill anything that is radiolabeled to avoid strict
cleanup procedures. Try not to set bottle or tube caps down on the surface of the hood
to avoid getting the hood contaminated with radioactive materials. Also, protect
micropipettes by not touching the sides of tubes containing isotopes with these
instruments.
11)Add the calculated amount of 3 H isotope to the tube for stock radiolabeled media and
mix well.
12)Transfer 1 mL of the media at this time for the 3 5s 3 H standard to the appropriate red-
cap freezer tube.
13) Freeze both standards along with the day 0 samples from this experiment.
14)As soon as you are done with the stock isotope solutions, place them back in the locked
refrigerator. Record the amount of each isotope used/remaining in the logbook.
15)Add 750 ptL of the radiolabeled media to each designated hydrogel sample.
16)Write down the start time for the 24-hour radiolabeling period on the printed sheet.
17)Add 750 ptL of PBS 1X with 1% PSA to empty wells to prevent contamination.
18)Make sure to mark all the plates that contain radiolabeled media with Rx tape. Specify
which wells are radiolabeled or empty.
19)Place the plates back in the incubator at 370 C for 24 hours so that the isotopes can be
incorporated into the cell-seeded hydrogel samples.
20) Clean up tubes with leftover media and verify micropipettes
a) Once you are done with the tubes that had radiolabeled media in them, clean them
by pouring any leftover media into the radioactive waste bin in the wet lab. Rinse
the tubes with a small amount of DI water which must be poured into the bin as
well. The empty tubes must be disposed of in the radioactive waste trashcan for 3H,
not 35S, since 3H has the longer half-life of the two isotopes.
b) Fill out the tags on both the bin and the trashcan to specify the amount of
radioactive waste. The required information can be calculated using the results of
the "Calculation Sheet for Solutions" spreadsheet.
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c) Verify if the micropipettes were contaminated with radioactive materials by using
the Geiger counter in the wet lab. If they are contaminated, you should wipe the
micropipettes with 70% ethanol and dispose of them in the radioactive waste
trashcan for 3H.
Radiolabel Takedown
Materials:
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e Pre-weighed red-cap freezer tubes for storing hydrogel samples, mark Rx as needed
e Labeled mini test tubes for saving radiolabeled media from gels, mark with Rx tape
e Labeled mini test tubes for saving unlabeled media from gels
e Sterile spatulas (bent spatula and pointed spatula) to remove hydrogels from their
wells
e 24-well plate(s) for transferring non-radiolabeled hydrogels
e 50 mL Falcon conical tube for Rx Wash
e 50 mL Falcon conical tube for radiolabeled wash waste, mark with Rx tape
e Micropipette (1000 piL) and sterile tips
* Box for discarding radiolabled pipette tips
e Rx Wash (DI Water with 10% PBS lOX, 0.4% Proline, and 0.8 mM Sodium Sulfate)
e Petri dish for discarded 2% agarose rings
e 24-well plate(s) with cell-seeded hydrogel samples
1) Make sure that the following materials are ready before the 24 hours for radiolabel
incorporation and gel takedown are up. Prepare the tissue culture hood with these
materials.
a) Labeled red-cap freezer tubes for storing the actual hydrogels. The weights of these
tubes when empty must be recorded to allow for wet weight measurements later on.
b) Labeled mini test tubes for removing the radiolabeled media.
c) Rx Wash (DI Water with 10% PBS lOX, 0.4% Proline, and 0.8 mM Sodium Sulfate)
- Calculate amount of Rx Wash needed (4 washes with lmL/wash for each
sample)
- To make Rx Wash, you may use one of the 1 mL aliquots of 250X Rx Wash Stock
(DI Water with 11.5 mg/mL Proline and 35.5 mg/mL Sodium Sulfate) stored in
the refrigerator in the Tissue Culture Room. The 1 mL Rx Wash Stock must be
mixed with either 249 mL of PBS 1X, or 225 mL of DI Water and 25 mL of PBS
lox.
- Transfer the calculated amount of Rx Wash needed to a 50 mL Falcon conical
tube to avoid pipetting in and out of the large Rx Wash bottle.
d) Sterilized spatulas to move the hydrogels from their plates to the red-cap freezer
tubes.
2) Move non-radiolabeled hydrogel samples to a new 24-well plate using sterilized tools.
Transfer the media accompanying each hydrogel to its corresponding new location
using a 1000 pL micropipette with sterile tips. Place the 24-well plate with non-
radiolabeled hydrogel samples in the incubator at 37'C. The tips used must be
discarded in the radioactive waste bin.
Note: The reason for the transfer is to separate the non-radiolabeled samples from the
radiolabeled ones that must be refrigerated during the washes.
3) Once at the 24 hour point, transfer the radiolabeled media from each well to its
designated labeled mini test tubes using a 1000 ptL micropipette.
4) Immediately add 1mL of Rx Wash to each well containing a radiolabeled cell-seeded
hydrogel. Place the 24-well plate in the refrigerator for 30 minutes. This is Wash #1.
Note: The plates are placed in the refrigerator to slow cell metabolism and maintain
viability.
5) After the 30 minutes are up, remove the used Rx Wash solution and discard it in the 50
mL Falcon conical tube for radiolabeled wash waste. Add 1 mL of fresh Rx Wash to each
desired well and place the plate back in the refrigerator for another 30 minutes. This is
Wash #2.
6) Repeat the previous step for a total of 4 washes.
7) After the last wash, separate the hydrogel plugs from the 2% agarose rings and transfer
them to their corresponding pre-weighed red-cap freezer tubes.
Method 1: Use the pointed spatula to gently tap the edges of the ring and detach it from
the well. Use the bent spatula to lift the edge of the ring slightly and release it. The fluid
motion should allow the plug to float out of the ring. Remove the ring from the well
using the pointed spatula and use a Kimwipe to remove excess water from the spatula
without touching the hydrogel. Carefully place the plug in its designated red-cap
freezer tube using the bent spatula.
Method 2: Use the bent spatula to remove both the ring and the plug from the well and
place them on a petri dish. Use the pointed spatula to carefully cut the ring and detach
it from the plug. Lift the hydrogel with the bent spatula and use a Kimwipe to remove
excess water from the spatula without touching the hydrogel. Carefully place the plug
in its designated red-cap freezer tube using the bent spatula.
Note: Method 1 is preferred when working with peptide hydrogels, since these are
more fragile and could break apart easily. Both methods can be used for agarose
hydrogels.
8) Weigh the vials again to obtain wet weight of each hydrogel sample by subtracting the
weights of the empty tubes.
Note: The gel weights should be around 50 mg at most.
9) Once the samples have been weighed, place the tubes in the freezer. Make sure all
tubes and boxes are appropriately labeled and stored, especially radioactive materials.
10)Clean up and discard all radioactive materials appropriately.
a) Discard all the waste wash from the plate and the 50 mL conical tube in the liquid
radioactive materials bin in wet lab.
b) Discard the petri dish with 2% agarose rings and 24-well plate in the solid
radioactive materials trashcans.
c) Discard micropipette tips in the radioactive materials sharps containers in the
Tissue Culture Room.
d) Clean spatulas by rinsing them with DI water, spraying with 70% ethanol, and
wiping them down with a Kimwipe.
e) Fill out the tags on all radioactive materials containers as needed.
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Measurin2 Radioactivity
Materials:
e Red-cap freezer tubes with Rx hydrogel samples
e Red-cap freezer tubes with radiolabel standards (35S and 35S3H)
e 96-well plates for samples and radiolabel standards
e Optiphase Supermix Scintillation Fluid
e Micropipette (20 pL) and sterile tips
* Repeater pipette with 5 mL sterile tips
e Sticky, hard plastic and roller for covering plates
e Scintillation counter
1) Thaw hydrogel samples and radiolabel standards in a water bath at 37'C
2) Prepare plate map(s) for samples. Do not read the Day 0 samples, since they were not
radiolabeled. For the sample plate, you must leave one row between each type of
sample. Also, the scintillation counter reads certain rows together (i.e., A&E, B&F, C&G,
D&H) so repeats should be placed accordingly to minimize errors.
1 2 3 4 5 6 7 8 9 10 11 12
A
B
C
D
E
F
G
H
3) Prepare plate map for radiolabel standards. For the standards plate, you must leave
one row and once column between standards. They should be located at a diagonal
from each other. This prevents the highly-concentrated radiolabeled materials from
exchanging between wells and causing errors in readings. See sample map below.
1 2 3 4 5 6 7 8 9 10 11 12
A 35S A 35S B
B
C 35S3H A 35S3H B
D
E 35S A 35S B
F
G 35S3H A 35S3H B
H I I IIIII1
4) Vortex each sample/standard and immediately add 20 ptL of the sample/standard to its
corresponding well using the 20 tL micropipette with sterile tips.
5) Add 300 [tL of Optiphase Supermix Scintillation Fluid to each well using a repeater
pipette set at 3 with a 5 mL tip. (Note: Use the beige repeater pipette in the Wet Lab.)
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6) Cover the prepared 96-well plates with sticky, hard plastic using a small roller to
prevent air bubbles.
7) Vortex the covered 96-well plates.
8) Set the 96-well plates in the scintillation counter chamber. The "stop plate" should be
at the top and the plates that will be read should be right below it. Plates should have
the same orientation and labels should always face out.
9) Software: Micro Beta Windows
a) Set start shelf
b) Set wells to be read
c) Set protocol: Adjusted Dual Label 96 Well (found in General Group Protocols)
d) Read samples by clicking "Start" when the program is "READY"
Note: It takes 90 seconds to read one well. They are read two at a time every 4
rows (A&E, B&F, C&G, D&H).
10)Use "Rx Calcs" MS Excel sheet to convert CCPM1 and CCPM2 readings into 3 H and 35S
concentrations (nmol). The highlighted (yellow) areas must be input. The
concentrations can then be used to see the amounts of protein and proteoglycans in the
samples, which should be expressed in terms of the DNA content. These normalization
values are obtained from the DNA Assay.
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A.10 Aggrecan Extraction
Objective:
This protocol describes how to extract aggrecan from tissue-engineered constructs or
native cartilage. The goal is to obtain samples that have undergone sufficient purification
such that aggrecan molecules can be better observed and studied through atomic force
microscopy (AFM).
Procedure:
Extraction Solution Preparation
Materials:
e Sodium Acetate, Anhydrous, ACS Grade (CAS # 127-09-3)
e Guanidine Hydrochloride (Gu HCl), Molecular Biology Grade, Ultra Pure (CAS# 50-01-1)
e Protease Inhibitor Cocktail Tablets (Roche, Catalog # 11697498001)
e Milli Q Water in 15 mL Falcon Tube
e Four 1.5 mL tubes for prepared solutions
1) Determine the volume of Extraction Solution needed for samples
pig sGAG in samples * (1mL Extraction Solution / 120 [ig sGAG) = mL
Extraction Solution
Note: For tissue-engineered samples, make 1 mL of Extraction Solution for every
-40mg of tissue wet weight with sGAG content of -120 ptg (i.e., plug sGAG content is -3
pg/mg wet weight). Double the amount of Extraction Solution needed if using native
tissue instead of tissue-engineered samples.
2) Make desired volume of Guanidine HCl Solution (4M Guanidine HCl in 100mM Sodium
Acetate, pH -7.2)
a) Decide what volume of Guanidine HCl Solution should be prepared ( mL)
Note: This volume should be at least as much as the volume of Extraction Solution
needed, though it may be useful to have extra Guanidine HCl Solution (e.g., to make
GAG Assay standards).
b) Prepare 100 mM Sodium Acetate (FW 82.03)
Weigh g of Sodium Acetate and dilute in mL Milli Q Water
c) Prepare 4 M Guanidine HCl (FW 95.53)
Weigh g of Guanidine HCl and dilute in mL of 100 mM Sodium Acetate
Note: Guanidine HCl powder is an irritant and is toxic to the nervous system so it
should be handled in the fume hood. When diluting Guanidine HCl in 100 mM
Sodium Acetate, start with less than half of the desired total volume and add 100
mM Sodium Acetate as needed. This is due to the fact that Guanidine HCl expands
when dissolved and rapidly increases the total volume.
d) Adjust pH to -7.2 using appropriate buffers
3) Make desired volume of Protease Inhibitor Stock Solution (12.5x)
Dissolve tablet in 1mL of Milli Q Water to obtain a 12.5x solution
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Note: The above is based on the manufacturer's instructions for the Protease Inhibitor
Cocktail Tablets. This stock solution can then be added to the Guanidine HCI Solution at
1x concentration to inhibit a broad range of proteases and protect the aggrecan
molecules in the samples.
4) Prepare final Extraction Solution by mixing appropriate fraction of Protease Inhibitor
Stock Solution with Guanidine HC1 Solution
Volume of PI Stock Solution = (1x / 12.5x) * (Volume of Extraction Solution for Samples)
Volume of Gu HCl Solution = (Volume of Extraction Solution for Samples) - (Volume of
PI Stock Solution)
Dilute: pL of Protease Inhibitor Stock Solution + uL of Guanidine HCI
Solution
5) Use the Extraction Solution as soon as possible, since the Protease Inhibitor Stock
Solution is only good for 1-2 weeks if stored at 2 to 8'C, or 12 weeks if stored at -15 to -
250 C.
Guanidine Hydrochloride Aggrecan Extraction
Materials:
e Samples
e Scalpel
e Extraction Solution
e Shaker in Cold Room
e Microcentrifuge in Cold Room
e New tubes for each sample
1) Mechanically disrupt each sample. Using a scalpel to dice works well for tissue-
engineered plugs. If using native cartilage tissue, it may be good to pulverize and
homogenize.
2) Add appropriate volume of Extraction Solution to each sample (determined in previous
section).
3) Mix on shaker at 40C for 48 hours. (This is probably excessive but will maximize
proteoglycan extraction.)
4) Spin the samples for 0.5 - 1 hr at -16,000 x g in microcentrifuge at 40 C.
5) Transfer the clarified supernatant to a new tube and discard the pellet.
Cesium Chloride Density Gradient Centrifugation
Materials:
e Samples
e Cesium Chloride (CsCI), Molecular Biology Grade (CAS# 7647-17-8)
e Microbalance in Main Lab
e Centrifuge Tubes (Beckman, Polycarbonate Tubes, 7/16 x 1 3/8 in., Product #343778)
e Ultracentrifuge in Main Lab
e Fraction collection tubes and post-dialysis sample tubes
e Slide-A-Lyzer Dialysis Cassettes, 10,000 MWCO (Thermo Scientific, Product # 66383)
e Autoclaved beakers for dialysis
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* Sodium Chloride (NaCI), Molecular Biology Grade (CAS# 7647-14-5)
e Milli Q Water in beaker for dialysis
1) Add CsCl powder to each sample until solution density is 1.58 g/mL.
a) Approximate the amount of CsCl that must be added based on the sample volume.
b) Check the density by weighing a known volume of solution in a microbalance.
2) Transfer each sample to the Centrifuge Tubes appropriate for spinning in the
ultracentrifuge. Make sure to balance the ultracentrifuge rotor exactly!
3) Spin the samples for 72 hrs at -500,000 x g in the ultracentrifuge at 4C.
Note: Spin all samples as long and hard as possible to produce a good density gradient.
4) Immediately at the end of the spin, carefully pipette fractions of the sample.
Notes: Splitting 1 mL into -10 x 100 ptL fractions works well. Start by pipetting off the
very top and working down the tube. Be aware that a hard pellet of CsCl may form at
the bottom; the density gradient will likely still be sufficient for PG purification.
5) Measure the density of the fractions by weighing a known volume of solution in a
microbalance.
6) Combine fractions based on density in the fraction collection tubes.
D1 > 1.54 g/mL; 1.46 g/mL < D2 < 1.54 g/mL
7) Dialyze with 500 volumes of 1M NaCl for 12-24 hrs.
8) Dialyze with 500 volumes of MilliQ filtered, distilled H20.
9) Store purified samples in freezer at -20'C
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A.11 AFM Imaging Assay for Aggrecan
Objective:
Atomic force microscopy (AFM) can be used to image key molecules in cartilage tissue-
engineered constructs. This protocol describes how to prepare mica with an aggrecan
monolayer and how to image samples with AFM.
Procedure:
Preparing APTES-Mica for Imaging
Materials:
e APTES (3-aminopropyltriethoxysilane)
e One 50mL Falcon tube filled with MilliQ water
e Mica film
* Scissors, tweezers, and tape
e Box for treated mica storage
e Filter paper (Whatman, 90 mm o, Catalog # 1002090)
1) Mix 3 ptL of APTES (3-aminopropyltriethoxysilane) with 30 mL MilliQ water (0.01%
v/v). Shake gently by inverting the vial a few times.
2) Cut square pieces of mica (1 cm x 1 cm) inside a bio-hood. Cleave the mica by pressing
the square piece against paper tape and peeling slowly. Make sure the cleaved plane
comes off cleanly in one piece. Place the cleaved mica in a closed container with the
cleaved plane side up. Do not touch the cleaved plane.
3) Immediately after cleavage, place 50 pL (or enough to cover the entire surface but not
spill off) of the 0.01% APTES solution on the cleaved mica. Keep the mica in a closed
container with water to minimize evaporation of the solution. For example, use a
pipette tip box filled with water in the bottom. Mica can be place on the divider in the
middle. Incubate for 30 minutes at room temperature.
4) Rinse gently in a stream of 200 ptL MilliQ water for about 10 seconds. Dry the mica by
holding it vertically with tweezers and blotting its edge on a piece of filter paper.
(Nitrogen drying is another option.)
5) Store in a closed container to prevent dust from contaminating the surface. Use the
treated mica to prepare the aggrecan monolayer on the same day.
Preparing Aggrecan Monolayer
Materials:
e Aggrecan sample solution
* Box for temporary sample storage
e One 50 mL Falcon Tube filled with MilliQ water
e Filter paper (Whatman, 90 mm 0, Catalog # 1002090)
* One petri dish for final sample storage
1) Thaw the frozen aggrecan solution at room temperature.
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2) Dilute the aggrecan solution with MilliQ water to the desired concentration and volume
(i.e., 10-100 pg/mL and 50-100 iL/mica). Mixed the diluted sample well by pipetting
up and down a few times.
3) Incubate 50-100 iiL of the diluted aggrecan solution on the treated mica in a closed
container at room temperature. Again, prevent sample evaporation by having water in
the container. The incubation time can range from 20-60 minutes, depending on the
desired final monolayer density of aggrecan.
4) Rinse gently in a stream of 200 ptL MilliQ water for about 10 seconds. Dry the mica by
holding it vertically with tweezers and blotting its edge on a piece of filter paper.
5) Store the mica with aggrecan samples in a closed petri dish to prevent dust from
contaminating the surface. Image when the sample is completely dry. This may take at
least 4 hours. Overnight drying is preferred.
AFM Imaging
Materials:
e Petri dish with mica aggrecan samples
e Magnetic disks and custom adhesive tape
e AFM probe tip (NANOSENSORS, SuperSharpSilicon, 4 tm thick, Tip Type SSS-NCHR-10)
e Specialized tweezers with grove for AFM cantilever or tip handling
e NanoScope Ila Multimode AFM
Notes:
e AFM facilities are located in 13-5037
e Computer: Username = administrator,
Start the Instrument
1) Open the Nanoscope 5.31r1 program
before anything else.
2) Click the microscope icon on the left to
3) Turn the NanoScope Ila Controller on
back panel.
Password = afm2007
on the computer. ALWAYS open the program
enter imaging mode.
using the switch on the upper right corner of the
Setting upfor Imaging
1) Select the appropriate piezo. Current images are obtained with the J scanner.
a) E scanner: x-y direction: 10 Im; z-direction 2.5 pim
b) J scanner: x-y direction: 100 pim; z-direction 5 ptm
2) Glue the mica sample on the magnet with adhesive tabs. Use tweezers to
samples and avoid touching the sample surface.
3) Place the magnet on the top of the piezo tube.
4) Place the AFM head on the piezo and attach the springs to the head. Hol
tightly while you do this. Make sure it is ALWAYS securely attached.
5) Move the sample down by pressing "Tip Up" (the base moves down). Thi
damage to the tip and sample when you slide in the tip holder.
handle the
I the head
s prevents
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6) Select a cantilever or tip. Place the tip holder facing up (handle should be on the left)
and press down on the base to open the golden clasp that holds the chip. Carefully slide
the chip into the holder until you hit the groove. Make sure the cantilever chip is right-
side up (the step around the chip should be on the bottom).
7) Place the holder into the head at a 450 angle to the surface (or at an angle so the holder
and cantilever don't hit the stage). To do this, turn the holder upside down (handle
should be on the right). Fasten the holder on the AFM head by turning tightening the
knob in the back to bring down the platform with the screws.
8) Move the sample up by pressing "Tip Down" (the base moves up). This brings the
sample and the tip closer together for imaging and laser alignment.
9) Switch the mode to AFM & LFM. It is better to align the laser in this mode because it is
more sensitive and aligned parameters will transfer over to TMAFM mode. If this
proves difficult, switch the mode to TMAFM and then align.
10)Plug in the laser and align the laser spot onto the tip of the cantilever. Use the paper
method to obtain a concentrated laser spot and use the light microscope to optically
guide the laser spot to the tip of the cantilever by moving its position with the knobs in
the head. Take special care to optimize the parameters as follows: maximize the sum
(e.g., 6.8-7.2), set the vertical difference to 0 V, and set the horizontal difference to 0 V.
11)Switch the mode to TMAFM.
12) Placing the AFM on a tripod during imaging improves the image quality significantly by
reducing vibrations. Use extreme caution when setting the AFM on the tripod.
Setting up the Nanoscope Program
1) Go to auto tuning mode by clicking the tuning icon to find the cantilever
frequency. Set the frequency to 50-500 kHz, the target amplitude to 3V, and
offset to 10%. Click Auto Tune button. You should see an amplitude profile
clear peak.
2) Go back to image mode.
3) Check the selected scanner: Go to MICROSCOPES > SCANNER > E or J
4) Check the selected profile: Go to MICROSCOPES > SCANNER > Tapping Mode
5) Other parameters:
Scan Controls
a) Scan Size: 2 pm
b) Aspect Ratio: 1:1
c) X Offset: 0 nm
d) Y Offset: 0 nm
e) Scan Angle: 0
f Scan Rate: 0.5-1.0 Hz
g) Samples/Line: 256 (pre-scan image); 512 (high-quality image)
h) Slow Scan Axis: Enabled
Feedback Controls
a) SPM Feedback: Amplitude
b) Integral Gain: 0.2-0.4 (Make sure it is low enough to prevent feedback os
c) Proportional Gain: 0.6-0.8
resonant
the peak
with one
cillation.)
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d) Amplitude Setpoint: 0.6-2.0, or higher (For tapping mode, the lower the value, the
greater the contact force on the tip. Use a larger value to prevent tip damage, but
if this value is too large then the tip may lose contact with the surface.)
e) Drive Frequency: Should be determined by Auto Tune
f) Drive Amplitude: Should be determined by Auto Tune
Other Controls
a) Microscope Mode: Tapping
b) Z Limit: According to the piezo
c) Units: Metric
d) Engage Setpoint: 0.8-1.0 (The lower the value, the greater the engage force. Use a
larger value to prevent tip damage, but if this value is too large then the tip may
lose contact with the surface later on.)
e) Parm Update Retract: Disabled
Channel 1
a) Data Type: Height
b) Data Scale: 5 pim
c) Line Direction: Trace
d) Scan Line
e) Realtime Planetfit: Line
f) Offline Planefit: None
Channel 2
a) Data Type: Amplitude
b) Data Scale: 1 V
c) Line Direction: Retrace
d) Scan Line
e) Realtime Planetfit: Line
f) Offline Planefit: None
6) Press the Engage icon to bring the tip to the sample surface.
7) Once the tip is engaged, you should hear a beep sound and see images appear.
8) During imaging, pay attention to the piezo Z center position. Make sure it doesn't
exceed ± 150 V.
9) Avoid scanning any large dust by offsetting the imaging area with the software or
disengaging and changing the scanning area with the adjustment knobs. DO NOT use
the adjustment knobs if the tip has not been disengaged. This could damage both the
sample surface and the tip.
10)Click the Capture button to capture an image. The software will capture the next
complete image. If any parameters have been changed after the capture function is
activated, the capture function will be held until the next frame.
11)When you are done or want to move another area on the sample, disengage the tip.
Clean up
1)
2)
3)
Disengage the tip from the sample.
Unplug the laser.
Raise the tip from the sample so you do not damage the tip and the sample when you
take out the holder.
102
4) Take out the cantilever chip from the hold and put it back in the tip box.
5) Detach the springs from the head.
6) Put the sample away.
7) Turn off the controller.
8) Close the software.
Image Processing
Materials:
e AFM Image Files
e NanoScope 5.31r1 Software
e WSxM 4.0 Develop 10.1 Software
1) Using the NanoScope 5.31r1 Software, select the scan area and resolution for the image
file.
2) Flatten the image to allow for a more accurate height image. Note that the WSxM 4.0
Develop 10.1 Software also has a flatten feature but this seems to work better with the
NanoScope 5.31r1 Software.
3) Save the modified image file for further processing.
4) Using the WSxM 4.0 Develop 10.1 Software, open the image file through the heuristic
interface.
5) Adjust the color palette to the desired aggrecan molecule colors. Click on the palette
settings button, which looks like a rectangle with lines on top. Choose the Nanolux
color scheme.
6) Equalize the image for a more accurate depth representation. Click on the equalize
button, which looks like a triangle with lines on top. Move the left and right boundaries
by clicking the mouse buttons (left click on desired location of left boundary, right click
on desired location of right boundary).
7) Remove any undesired noise lines on the image. Click on the remove lines button,
which looks like three intersecting lines. Move the indicator in the scroll bar to the line
you want to remove and click OK.
8) Save the final image in a high-quality file.
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